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LIST OF ABBREVIATION 
 
ABC: activated B cell  
ADCC: antibody-dependent cell-mediated cytotoxicity 
AIRE: autoimmune regulator gene 
ALL: acute lymphoblastic leukemia 
ALPS: autoimmune lymphoproliferative disorder 
APS1: autoimmune polyendocrinopathy syndrome type 1 
BAFF: B cell activating factor 
BCR: B cell receptor 
BLIMP1: B lymphocyte-induced maturation protein 1 
BM: bone marrow 
BSA: Bovine serum albumin  
BTK: Bruton’s Tyrosine Kinase 
COO: cell of origin 
CTLA4: Cytotoxic T Lymphocyte Antigen 4 
CSR: class switch recombination 
DCs: dendritic cells 
DEG: differentially expressed genes 
DEL: double expressor lymphoma 
DHL: double hit lymphoma 
DLBCL: Diffuse large B cell lymphoma 
ds-DNA: double strand DNA 
DZ: dark zone 
ECM: extracellular matrix 
ELISA: enzyme linked immunosorbent assay 
EMT: epithelial to mesenchymal transition 
FBS: fetal bovine serum 
FcR: Fc receptor 
FDC: follicular dendritic cell 
FDR: false discovery rate 
FFPE: formalin-fixed paraffin-embedded 
FOB: follicular B  




GEP: gene expression profile 
GFP: green fluorescent protein 
HDAC: histone deacetylase 






iOPN: intracellular OPN 
IRES: internal ribosome entry site 
IRF: Interferon regulatory factor 
LYN: LCK/YES novel tyrosine kinase 
LN: lymph node 
LPR: lymphoproliferation 
LPS: lipopolysaccharide 
LZ: light zone 
MHC: major histocompatibility complex 
MS: multiple sclerosis 
MMP: metalloproteinase 
MRL: Murphy Roths Large  
MYD88: myeloid differentiation primary response 
MZB: marginal zone B 
MZM: marginal zone macrophages 
NHL: Non-Hodgkin Lymphoma 
OPN: Osteopontin 
PBS: phosphate buffered saline 
pDC: plasmacitoid dendritic cell 
Poly I:C: polycytidylic-inosinic acid potassium salt 
PRDM1: PR Domain Zinc Finger Protein 1 
RA: rheumatoid arthritis 
R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone 
RGD: arginine-glycine-aspartate 




shRNA: short hairpin RNA 
siRNA: small interfering RNA 
SLE: systemic lupus erythematosus  
SLO: secondary lymphoid organs 
sOPN: secreted OPN 
SPP1: Secreted phosphoprotein 1 
ss-DNA: single strand DNA 
STAT: signal transducer and activator of transcription 
T conv: conventional T cells 
Tfh: T follicular helper 
TLR: Toll-like receptor 
TM: tumour 
TNF: tumour necrosis factor 
Treg: T regulatory cells 
VDJ: variable, diversity, joining 









































































































Several studies have highlighted the association between certain autoimmune diseases 
and increased occurrence of hematological malignancies, such as Systemic lupus 
erythematosus (SLE).  Patients affected by SLE have indeed a high risk of developing 
non-Hodgkin lymphoma (NHL), mostly diffuse large B cell lymphoma (DLBCL). 
Osteopontin (OPN) has been associated with SLE pathogenesis, as SLE patients have 
increased serum levels of OPN and often polymorphisms in SPP1, the gene encoding 
for OPN.  
To study the role of this molecule in autoimmunity-associated lymphomagenesis, the 
Faslpr/lpr mutation of the autoimmunity-prone mouse strain has been transferred onto a 
OPN-deficient background. Interestingly, OPN-/-Faslpr/lpr mice showed a significantly 
higher incidence of splenic B cell lymphomas in comparison to Faslpr/lpr mice. Indeed, in 
OPN-deficient autoimmune mice we observed an expansion of mature CD19+IgM-
CD23-CD21/35- cells, which showed the typical signature of the activated type of 
DLBCL (ABC-DLBCL), BCL6-, BCL2+, c-MYC+, IRF4+, Ki67hi, and a striking 
activation of the STAT3 pathway. Additionally, OPN-deficient autoimmune CD19+ B 
cells showed a baseline hyper-activation of Toll-like receptor 9 (TLR9)-dependent 
MYD88 signaling pathway, and were more activated when stimulated with the TLR9 
agonist CpG 1826, which mimics double strand-DNA circulating in autoimmune 
conditions. Immunohistochemistry on splenic tissues and immunofluorescence staining 
on CD19+ cells showed that CD19+ B cells from Faslpr/lpr mice express the intracellular 
isoform of OPN at the endosomal surface, where TLR9 is also located. To gain 
mechanistic insights, I genetically modified ABC-DLBCL cell lines, derived from 
lymphomatous spleens of OPN-/- mice, to over-express either the soluble (sOPN) or the 
intracellular isoform of OPN (iOPN). Remarkably, in vitro experiments showed that 
iOPN was able to prevent the CpG-mediated activation of STAT3 and, partially, of 
NFkB pathway, suggesting a negative regulatory role for iOPN in this setting. 
Additionally, when injected in vivo, while the over-expression of sOPN conferred a 
growth advantage over control cells, iOPN-expressing cells were less tumorigenic.  
Interestingly, other than B cell-intrinsic, the molecular mechanisms at the basis of the 
aggressive lymphomagenesis observed in OPN-/-Faslpr/lpr mice were also likely stroma-
related. Indeed, mainly myeloid cell subsets of the splenic microenvironment of OPN-
deficient autoimmune mice expressed more Tnfsf13B (encoding for BAFF) and Il6, both 




counterparts. Interestingly, in lymphomatous areas of the spleen from OPN-deficient 
mice, a high number of infiltrating CD8+ T cells with an activated morphology was 
notable. However, their analysis by flow cytometry showed markers of exhaustion 
(TIM3 and PD1), suggesting that, despite being recruited at the tumour site, they were 
likely dysfunctional and unable to contrast tumour expansion. 
The translational relevance of these findings comes from the analysis of ABC-DLBCL 
biopsies that expressed a lower SPP1/OPN level than GC-DLBCL counterparts, 
suggesting how a diminished expression of B-cell intrinsic OPN may be associated with 
the development of the most aggressive DLBCL. However, the existence of a specific 
intracellular form and/or localization of OPN in humans remains to be investigated. 
Altogether, my data suggest that B cell-intrinsic iOPN is contrasting autoimmunity-
driven ABC-DLBCL development, also in concert with microenvironment-related 














1.1 Autoimmune disorders 
 
Autoimmune disorders affect 5-8 % of the population worldwide, with approximately 
75 % of patients being women [1]. So far, there have been described more or less one 
hundred distinct autoimmune diseases, characterized by different causes, symptoms and 
molecular features. 
At the basis of the pathogenesis of all disorders there is a breach in the so-called 
“immunological tolerance”, which is the ability of the immune system to prevent itself 
from targeting self molecules, cells or tissues. The impairment of this process leads, at 
the end, to tissue damage at certain sites. Indeed, according to the organs involved, 
autoimmune diseases are classified into organ specific (i.e. Graves’ hyperthyroidism) 
when a single organ is interested, or systemic (i.e. Systemic lupus erythematosus), in 
case multiple organs are damaged.  
The effector mechanisms of tissue destruction in autoimmune diseases are essentially 
the same of those acting in protective immunity and in hypersensitivity diseases [2]. 
Autoimmune disorders can be classified, according to their immune effector pathways, 
in type II (antibody-mediated), type III (immune complex-mediated), and type IV (T 
cell-mediated) diseases.  
 
 
Figure 1. Immunological mechanisms of hypersensitivity diseases [2].  
 
A common feature of autoimmune diseases is the presence of autoantibodies, whose 




lysis. In this process, complement activation and/or antibody-dependent cell-mediated 
cytotoxicity (ADCC) are the most common pathways of destruction. As an example, in 
autoimmune hemolytic anemia, patients produce IgG or IgM that bind the Rh self-
antigen on red cells. These cells are then rapidly cleared from the circulation by 
phagocytes, that interact, through their own Fc receptor, with the Fc constant region of 
Ig) and, through their own complement receptor, with complement system tied to IgM. 
Alternatively, the autoantibody-bound red cells are lysed by formation of the 
membrane-attack complex of complement  [2]. 
Immune complexes are formed whenever an antibody binds to a soluble antigen. In 
physiological conditions, immune complexes are efficiently phagocytized by cells 
bearing Fc receptors and/or complement receptors, thus causing little damage. 
However, the immune complexes clearance could fail when a large amount of antigens, 
and the subsequent immune-complex deposition in blood vessels and organs, 
overwhelm the activity of the mononuclear phagocytic system. This is the case of 
systemic lupus erythematosus (SLE), an autoimmune disease caused by chronic IgG 
antibody production directed at ubiquitous self-antigens exposed on dead and dying 
cells and released from injured tissues. This leads to a continuous formation of immune-
complexes, that, deposited in blood vessels and renal glomerulus, cause vasculitis and 
glomerulonephritis, respectively [2].  
The third type of effector mechanism of damage in autoimmune diseases is mediated by 
effector T cells, that are specific for auto-antigens expressed through self MHC-I. As an 
example, in type 1 diabetes insulin-producing pancreatic beta cells are destroyed by 
cytotoxic T cells, that recognize insulin as non self, even though it is not the exclusive 
identified antigen in the pathogenesis of the disease [2,3]. 
Most autoimmune disorders are multifactorial diseases, as both genetic and 
environmental factors converge in their development. Among the rare monogenic 
autoimmune diseases, autoimmune polyendocrinopathy syndrome type 1 (APS1) is 
driven by a defect in the autoimmune regulator (AIRE) gene [4], encoding for the 
homonym transcription factor, which normally orchestrates the so-called “thymic 
education” [5]. Specifically, AIRE, expressed by the medullary thymic epithelial cells, 
allows them to express organ-specific proteins and to present them to thymocytes, the 
precursors of T cells, that, in turn, will be tolerant against these self-epitopes once they 
will reach the periphery. Indeed, in case of genetic abnormalities in the AIRE gene, 




hypothyroidism, pernicious anaemia, type 1 diabetes, hepatitis, gastritis and alopecia 
[6]. 
The majority of autoimmune disorders are not monogenic, but rather they involve 
multiple genetic factors that contribute in causing the disease and that often codify for 
molecules playing a role in innate or in adoptive immunity. A variety of studies have 
shown that numerous genetic variants of the major histocompatibility complex (MHC) 
are associated with autoimmune diseases [7].  MHC locus encodes for molecules, 
termed human leucocyte antigens (HLAs), involved in antigen presentation and 
therefore critical in distinguishing self from non-self. To make some examples, variants 
of HLA-B27 are associated with ankylosing spondylitis and acute anterior uveitis, while 
altered sequences in HLA-DR3 can promote Graves’ disease and SLE, and HLA-DR4 
allele variants are risk factors for rheumatoid arthritis. Other than mutations in MHC 
sequence, also genetic defects in other genes with functions in immune processes can 
cause specific autoimmune diseases, such as mutations in genes encoding for the 
complement system (C3, CR4 and CR1Q units), the critical pathway for removing 
immune-complexes and apoptotic cells from the circulation, that are associated with 
SLE [8]. 
Additionally, also defects in Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), a receptor 
that switches off their inflammatory status to restore homeostasis, once they have 
exerted their functions, are risk factors for rheumatoid arthritis, SLE and Type 1 
diabetes [9]. 
Remarkably, an impaired apoptosis of lymphocytes, caused by mutations in the TNF 
(tumor necrosis factor) family death receptor Fas and/or in its ligand FasL, can sustain 
the autoimmune lymphoproliferative disorder (ALPS) and SLE [10] [11]. Interestingly, 
a loss of function mutation in the gene encoding Fas represents the genetic basis of the 
syndrome of lymphoproliferation and autoimmunity characteristic of the lpr mouse 
strain, which has always been used as model for human SLE [12].  
Autoimmunity can be also modulated by epigenetic mechanisms, that control gene 
packaging and expression independently from alterations in the DNA sequence. As an 
example, insulin DNA hypermethylation is associated with type 1 diabetes [13], while 





Surprisingly, the concordance rate of autoimmune disease in monozygotic twins ranges 
from 12 % to 67 %, suggesting that, other than genetic dynamics, also factors 
environment-related are involved [15]. Environmental factors could include nutrition, 
microbiota, infectious agents, tobacco smoke, use of pharmaceutical drugs and heavy 
metals. To explore the connection between infections and autoimmunity, the example of 
acute rheumatic fever is very exhaustive. Genetically susceptible people may develop 
this disease following exposure to Streptococcus pyogenes [16]. The phenomenon at the 
basis of this pathogenesis is the so-called “molecular mimicry”, in which 
microorganism antigens resemble host epitopes. In the specific case of acute rheumatic 
fever, the bacterial M protein has an amino acid sequence very similar to the human 
lysoganglioside, a protein expressed in kidney and heart, causing an autoimmune 
response and chronic damages to these organs. 
The molecular mimicry is connected with another important mechanism, the “epitope 
spreading” [17]. This process occurs when, in such inflammatory scenario, cells 
damaged by virus infections and inflammatory milieu start to expose secondary self-
antigens. This switch from the “dominant” epitope to neo-epitopes gives rise to the so-
called “bystander activation” [18], through which it is generated an activation cascade 
of lymphocytes that start fighting the new antigens, fostering autoimmunity.  
Additionally, smoking is by far one of the most important risk factors for rheumatoid 
arthritis [19] as well as for SLE [20], since cigarettes contain several Toll-like receptor 
(TLR)-stimulating molecules, including lipopolysaccharide (LPS), a TLR4 agonist that 
can elicit an innate immune response. 
At present, a therapy that completely cures an autoimmune disease does not exist. 
Patients are usually treated with immunosuppressive drugs: glucocorticoids that 
suppress the whole immune system [21], methotrexate that inhibits the metabolism of 
folic acid in T and B cells [22], purine analogues that inhibits DNA synthesis [23], TNF 
and IL-6 inhibitors [24] [25] and rituximab (the anti-CD20 antibody that selectively 
depletes B cells) [26]. Of note, immunosuppressive drugs are known to promote severe 
adverse events, for example increased susceptibility to infection and augmented risk of 
malignancy [27].  
 
1.1.1 Systemic lupus erythematosus 
 
Systemic lupus erythematosus (SLE) is a rare systemic autoimmune disease with 




symptoms, including fatigue, fever, joint and muscle pain and the most known skin 
problems. Among the latter, the red “butterfly rash” across the cheeks is the most 
common, but also vasculitis and the development of tiny red spots (petechiae) may 
occur. Affected individuals could also have alopecia and ulcerations in the mucosae of 
the mouth, nose, or, less commonly, the genitals. 
As mentioned before, SLE is a pathology mediated by immune complexes and, like all 
autoimmune disorders, a dysfunction of both innate and adoptive immunity is at the 
basis of its pathogenesis. Self-antigens (nucleic acids and their binding proteins) 
complexed with their cognate autoantibodies, directly contribute to the activation of 
both innate immune cells via Fc receptor (FcR)-mediated uptake of complexes, and B 
cells, through an initial engagement of the B cell receptor (BCR). Then, the nucleic acid 
component of these complexes engages intracellular TLRs, promoting inflammatory 
pathways with a subsequent activation of other innate cells and lymphocytes [2].  
Although cases of monogenic lupus, caused by mutations of complement component 1q 
(C1q), three-prime repair exonuclease 1 (TREX1), or deoxyribonuclease 1-like 3 
(DNASE1L3), do exist [29], in most cases this pathology results from a combination of 
multiple genetic abnormalities. Several human allelic variants have been identified as 
risk factors for SLE [30]. TREX1, DNASE1, autophagy related 5 (ATG5), and 
RAD51B encode for proteins functionally related to mechanisms of apoptosis, DNA 
degradation, and clearance of cellular debris, all processes involved at autoantigen 
formation and release. TLR7, TLR8, TLR9, Interferon regulatory factor 5 (IRF5), IRF7 
and signal transducer and activator of transcription 4 (STAT4), are involved in nucleic 
acid sensing and type I interferon (IFN-I) production by antigen-presenting cells, events 
that generate a pro-inflammatory environment. Other human mutations associated with 
SLE affect proteins involved in T and B cell function and signaling, and include non-
receptor type protein tyrosine phosphatase 22 (PTPN22), TNFSF4 (tumor necrosis 
factor superfamily member 4) and LCK/YES novel tyrosine kinase (LYN), molecules 
that decrease the activation threshold of CD4+ T and B cells upon auto-antigen 
encounter [31]. 
Interestingly, also epigenetic modifications have been linked to SLE. In particular, in T 
cells from SLE patients, autoimmunity-related genes, normally suppressed by DNA 
methylation, undergo hypomethylation, leading to protein over-expression. Among 
these genes, interleukin (IL)-6, IL-10, CD40L and IRF7 are noteworthy to be mentioned 




lymphocytes from MRL/lpr lupus-prone mice [34] and in CD4+ T cells from SLE 
patients [14]. As an example, in human SLE T cells, which are defective in the 
production of IL-2, IL-2 gene is silenced by the histone deacetylase 1 (HDAC1), that, 
once recruited to the IL-2 promoter, acts via histone H3K18 deacetylation [35]. 
A deregulation in either the number or function of different immune cell populations is 
a well-recognised feature of SLE [36]. CD4+ T cells, for example, show compromised 
effector capacities, due to a severe defect in IL-2 production. On the other hand, IL-17, 
is massively released by CD4+, T helper (Th) 17 and autoreactive CD4-CD8-
CD3+B220+ T cells, thus increasing the inflammatory response mostly via recruitment 
of neutrophils. A dynamic subset of T helper cells, T follicular helper (Tfh) cells, play a 
crucial role in SLE, since they produce IL-21, which drives B cell maturation and high-
affinity autoantibodies production. Remarkably, in SLE patients and mouse models, an 
uncontrolled expansion of these cells, characterized by CXCR5+PD1+OX40+ICOS+ 
expression, is observed [37], and their abundancy in the circulation correlates with 
plasmablast B cell number and anti-DNA autoantibodies in patients [38]. Additionally, 
both human and mice affected by this disease show multiple B cell abnormalities, 
including B cell lymphopenia and B cell hyperactivity. In B cells from SLE patients, 
indeed, a pronounced activation of the BCR is observed, as a result of a strong 
phosphorylation of SYK and BTK [39]. Both kinases, of note, other than belonging to 
the BCR cascade, mediate a crass talk between BCR and TLRs, as well as BCR and 
JAK/STAT3 pathway. 
Interestingly, another protein important for B cell activation contributing to SLE 
pathogenesis is MYD88, an adaptor molecule involved in TLR signaling cascades. 
Notably, B cells from MRL/lpr mice are dependent on MYD88 for autoantibody 
production [40]. 
Among the different innate immune populations, a reduced phagocytic activity was 
observed in neutrophils, despite their strong infiltration in tissues. Importantly, their 
presence has been linked to lupus damage via the extrusion of neutrophil extracellular 
trap (NETs), source of double strand DNA auto-antigens [41]. 
In addition, a specific subpopulation of dendritic cells, namely plasmacytoid dendritic 
cells (pDCs), existing both in humans and mice, play a pivotal role in SLE 
pathogenesis. Specifically, pDCs produce a large amount of type I interferon (IFN-I), 
known to directly promote T cell activation and survival [42] [43], and B cell response 




Least but not last, a particular class of splenic macrophages, called “marginal zone 
macrophages” (MZMs), harboring a unique capacity to clear apoptotic cells and induce 
tolerogenic signals via TGF-β and IL-10, show a reduced phagocytic capacity and 
survival in SLE patients and lupus-prone mice [36].   
From a clinical point of view, due to the heterogeneity of symptoms and pathologic 
processes, SLE has been one of the most challenging diseases to understand and treat 
and, unfortunately, most of all clinical trial have so far failed to show efficacy [46].   
 
1.1.2 Faslpr/lpr mice, a model of SLE-like syndrome 
 
FAS, also known as apoptosis antigen 1 (APO-1), cluster of differentiation 95 (CD95) 
or tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein that is 
encoded by FAS gene, located on chromosome 10 in humans and on chromosome 19 in 
mice. After crosslinking with its ligand FASL, FAS receptor promotes the extrinsic 
pathways of programmed cell death (apoptosis) via the activation of caspase-8. 
The mutation of the mouse Fas gene was described for the first time in 1978 by 
Andrews et al. [47], who, while establishing the autoimmune-prone Murphy Roths 
Large (MRL) mouse strain, discovered a mouse mutant showing splenomegaly and 
lymph-adenopathy. The identified autosomal recessive mutation was defined as lpr (for 
lymphoproliferation) and mice were termed MRL/lpr.  
Interestingly, a phenotype similar to that observed in MRL/lpr mice was discovered few 
years later [48] and the autosomal recessive mutation responsible, termed gld (for 
generalized lympho-proliferative disease) was found to be located in FasL gene. The 
fact that severe autoimmune disorders are caused by these mutations highlights the 
importance of FAS-FASL interaction in lymphocyte homeostasis.  
The lpr mutation results from the insertion of an early transposable element (ETn), 
similar to an endogenous retrovirus, into the intron 2 of the gene encoding Fas [49]. 
Since this ETn carries two poliA adenylation sites, transcription of Fas prematurely 
terminates in intron 2, leading to an inhibition of its expression.  
The FAS defect causes an aberrant expansion in the secondary lymphoid organs (SLO), 
spleen and lymph nodes, of the so-called “double negative” T cells, since they do not 
express neither CD4 nor CD8, while retaining CD3 and B220 markers. The expansion 
of this population is due to an impaired “thymic education” of the auto-reactive 
thymocytes, that, lacking FAS, do not die through apoptosis, but survive and 





                               
 
Figure 2. Consequences of Fas mutation in Faslpr/lpr mice. [edited, 140] 
 
It is not surprising that similar genetic defects and phenotype characterize autoimmune 
disorders in humans. As an example, the autoimmune lymphoproliferative syndrome 
(ALPS) is a consequence of mutations of FAS, FASL or other apoptosis-related 
molecules such as caspase 10 [50]. Interestingly, splenomegaly, lymph adenopathy, 
thymic enlargement and splenic infiltration of double negative (DN) T cells are 
hallmarks of ALPS.  
MRL/lpr mouse strain is one of the best-studied models for spontaneous lupus, since 
these mice show many of the features observed in SLE patients. Lupus-prone mice 
exhibit serum autoantibodies against self-nucleic acids at about 6 weeks of age, while 
initial lymph-adenopathy is observed starting at 12 weeks [51].  
Importantly, other than promoting SLE-like syndrome, the lpr mutation predisposes 
mice to malignant lymphomas later in life, in particular B cell malignancies [52]. This 
reflects the well-known and widely documented association between autoimmune 
disorders and hematological malignancies in humans, and allowed us study the early 






1.2 The association between autoimmune disorders and haematological 
malignancies  
 
Over the years, several studies have pointed out that certain autoimmune and chronic 
inflammatory conditions, including rheumatoid arthritis, Sjögren's syndrome, SLE, 
psoriasis and celiac disease are associated with an increased occurrence of lymphoma 
[53]. 
As an example, in a pooled analysis of nearly 30000 patients with non-Hodgkin 
lymphoma (NHL) [54], SLE and Sjogren’s syndrome were associated with a 2.7- and a 
6.5-fold increase risk of B cell NHL, respectively. On the other hand, T-cell mediated 
autoimmune disorders, such as celiac disease and psoriasis, were associated with 
increased risk of T-cell NHL [54]. 
According to Smedby et al. [55], the risk of developing diffuse large B cell lymphoma 
(DLBCL), a specific subtype of NHL, was elevated among patients with rheumatoid 
arthritis, Sjögren syndrome, SLE or celiac disease. Specifically, in the case of SLE, 
patients affected by this disorder showed a 4.6-fold increase in all NHL and a 6-fold 
increase in DLBCL. 
However, despite all the studies considered a huge number of patients and clearly 
support a link between autoimmunity and lymphomagenesis, values describing the 
increased risk for each disease vary considerably among studies. In addition, it is not so 
clear whether the risk of developing tumours concerns equally all individuals affected 
by a specific autoimmune disorder or changes according to phenotype and treatment. 
More robust, is the observation that the existing link may be related only to specific 
subtypes of NHL [56]. 
Expectedly, immunosuppressive therapies used in the treatment of autoimmune diseases 
have long been suspected to play a role in the development of lymphomas in these 
individuals, but epidemiologic studies have failed to demonstrate this “cause and effect” 
relationship [57]. More recently it has been investigated whether the new biological 
agents, especially those targeting TNF, could be the cause of the high incidence of 
lymphomas. While very few studies converged on this idea [58], large population-based 
studies have failed to demonstrate an increased risk with the use of anti-TNF drugs [59]. 
Indeed, the prevailing opinion is that immunomodulatory biologic agents seem not to 
increase the risk of lymphoma development. 
About the possible mechanisms for progression of autoimmune diseases to lymphomas, 




autoimmunity and hematologic malignancies are similar. The most prominent example 
is the finding that FAS mutations, as already mentioned, are associated with both 
autoimmune diseases and lymphomas in mice and in humans. Importantly, autoimmune 
disorders are characterized by a chronic inflammatory state due to the persisting 
presence of auto-antigens, leading to a massive T and B cells activation. Thus, the high 
proliferative rate of these cells, along with the consistent amount of cytokines secreted 
by the whole immune system, increase the possibility of transforming events. 
Furthermore, such an inflammatory scenario induces, in the SLO microenvironment, 
modifications in the number, distribution, and phenotype of immune cell populations, as 
well as a remodeling of tissue architecture. These articulate mechanisms could be 
crucial in sustaining autoimmune proliferation. 
 
1.3 B cell lymphomas  
 
Lymphomas are a heterogeneous class of tumours generated from B cells (80 %) and 
less frequently from T cells (20 %) [60]. Such difference is due to the occurrence of 
aberrant processes, namely class switch recombination (CSR), somatic hyper-mutation 
(SHM) and receptor editing, involving genic alteration during B cell development, thus 
increasing the possibility of transforming events. 
B cell development starts in the bone marrow, where lymphoid progenitors will become 
immature B cells, following a precise sequence of stages aimed at exposing a correct 
and functional B cell receptor (BCR) on the cell surface [61]. The assembly of genes for 
the variable region of both heavy and light chain is mediated by a process called V(D)J 
recombination. Specifically, the variable region of the heavy chain is formed by 
assembling the V (variable), D (diversity) and J (joining) segments, while those of the 
light chain (that can be k o λ) are assembled from V and J segments.  
During the first phase, pro B cells, which do not exhibit any gene rearrangement and 
therefore immunoglobulin expression, become pre-B cells, characterized by the 
exposure of the pre-BCR, composed by a constant region associated with the surrogate 
light chains. Pre-B cells, after undergoing V-J rearrangement of the light chains, 
become immature B cells with a complete BCR. At the end, only cells that have 
rearranged BCR with the correct open reading frame, as well as cells with a BCR 
insensitive to self-antigens, survive. Indeed, newly formed B cells expressing auto-




V(D)J rearrangement, a process termed “receptor editing” [62].  
At this point, immature B cells leave the bone marrow and reach the secondary 
lymphoid organs (spleens, lymph nodes, mucosa-associated lymphoid tissue) where, 
after encountered an antigen, will definitely become mature [61]. Driven by antigen 
stimulation through BCR and the CD40-CD40L-mediated interaction with T cells, B 
cells enter the germinal center (GC) microenvironment, where they proliferate and 
undergo clonal expansion. In order to generate high-affinity antibodies, single-base 
changes are introduced by a mechanism termed SHM into the variable regions of the 
immunoglobulin. Concurrently, with the goal of generating a variety of antibodies with 
different effector properties, the immunoglobulin constant region undergoes a series of 
recombinations known as CSR, whereby different subclasses of antibodies (IgG, IgA or 
IgE) are produced. Finally, the proliferating B cells, referred as centroblasts, that 
produce high-affinity antibodies, either differentiate into plasma cells to suddenly 
secrete large quantities of antibodies, or become memory B cells, programmed to 
recognize antigens after future exposures.  
Altogether, these processes occur in specific follicle structures, the germinal centers 
(GC), which are compartmentalized in two anatomically distinct areas: the dark zone 
(DZ), close to the T cell zone, populated by rapidly dividing centroblasts, and the light 
zone (LZ), which is composed by smaller non-dividing centrocytes  [63,65]. The master 
regulator of the GC reaction is BCL6, responsible for the proliferative status of GC 
cells, that allows the execution of SHM and CSR and prevents a premature 
differentiation of GC B cells by repressing BLIMP1. B cells leave the DZ to enter the 
LZ, enriched in follicular dendritic cells (FDC) and T follicular helper cells (Tfh), both 
playing a fundamental role in promoting B cell survival and response. Here, centrocytes 
display an activated phenotype, including a high expression of activation markers such 
as CD86 and CD83. Indeed, a series of signals like crosslinking of BCR by the antigen, 
CD40-CD40L interaction and stimulation of TLRs activate downstream signaling 
cascades, such as NF-κB pathway. This leads to the expression of IRF4, that represses 
BCL6 transcription, thus restoring the expression of BLIMP1, which enables plasma 
cell differentiation. Together, the antigen encounter and the activated phenotype 






Figure 3. The dark and the light zone of the germinal center[65]. 
 
Disruption of steps in normal B cell differentiation, including V(D)J, SHM and CSR, 
can result in the genesis of B cell lymphomas. For example, the t(14;18) translocation 
involving the IGH and BCL2 genes occurs from a mistake in VDJ process and results in 
the overexpression of BCL2 in follicular lymphoma [66]. Additionally, in Burkitt 
lymphoma SHM is likely involved in t(8;14) translocation of IGH and c-MYC [67], the 
latter brought under the control of the IG enhancer elements leading to its constitutive 
transcription. Furthermore, an aberrant switch recombination involving BCL6 and c-
MYC was found to be responsible for translocations in the activated type of DLBCLs 
[68]. 
 
1.3.1 Diffuse Large B cell lymphoma 
 
B cell lymphomas comprise two categories of malignancies: the rare HL, characterized 
by the presence of Reed-Sternberg cells, and the more common and heterogeneous 
NHL.  
DLBCL is the most common type of NHL worldwide, comprising 30-40 % of all new 
diagnoses [64]. Histologically, lymphomatous cells are large, with abundant cytoplasm 
and prominent round-ovoid nuclei with thick nuclear membrane and multiple nucleoli. 
Based on the cytological aspects, DLBCL can be divided into several variants. The 
most frequent variant is the centroblastic DLBCL (80 % of cases) where the cell 
population is composed of cells resembling the centroblasts of the GC; in the 
immunoblastic variant, which represents 10 % of the DLBCL, almost the entire 
neoplastic population is constituted by immunoblasts. Finally, in the anaplastic variant, 





Although a substantial proportion of patients is cured by R-CHOP (Rituximab, 
cyclophosphamide, doxorubicin, vincristine, prednisone) immune-chemotherapy, about 
40% of cases do not achieve durable remissions [64]. A reason for such a lack of 
success is the heterogeneity of this malignancy, both in terms of molecular pattern and 
clinical manifestations, other than the response to therapy. Interestingly, it was with the 
introduction of genome and transcriptome analysis, which allowed the recognition of 
multiple genetic and transcriptional signatures, that DLBCL could be classified 
according to different criteria, namely the cell of origin and the oncogene 
amplifications. Very recently, a new classification of DLBCL has been created, based 
on the mutational burden [69]. The most common classification refers to the cell of 
origin (COO), and, according to this parameter, DLBCL are subdivided into germinal 
center B cell-like (GCB) and activated B cell-like (ABC) subtypes, while about 15 % of 
cases are unclassifiable [64].  
 
 
Figure 4. The genetic landscape of GC- and ABC-DLBCL [64]. 
 
The GC-DLBCL seems to be more related to light zone GC B cells [70], while ABC-
DLBCL is transcriptionally more reminiscent of plasmablasts [71,72]. Specifically, 
GCB-DLBCLs display high-level expression of CD10 and BCL6 and harbor hyper-




activation of NFkB and BCR signaling pathways, and an up-regulation of genes, such 
as IRF4, required for plasmacytic differentiation. 
Although GC- and ABC-DLBCL have a distinct genetic landscape, the two subtypes 
may share some abnormalities [64]. As an example, 30 % of cases, with some 
preference for GC-DLBCLs, harbor mutations and/or deletions inactivating the 
acetyltransferase CREBBP, while about one third of DLBCLs show mutations in the 
MLL2 gene, which encodes for the homonym methyltrasferase. Notably, chromosomal 
rearrangements of the BCL6 locus characterize as many as 35 % of DLBCL, with ABC-
DLBCL patients being from two to three times more susceptible. Furthermore, in more 
or less 30 % of cases, the beta-2-microglobulin (B2M) gene, encoding for a subunit of 
the HLA- I complex, is mutated or deleted, as a mechanism of immune surveillance 
escape [64].  
As concern genetic lesions specific for the GC type of DLBCL, about 40% and 10-14 % 
of patients harbor the chromosomal translocations of BCL2 and MYC, respectively. In 
addition, 10 % of GC-DLBCL patients show deletion of the tumor suppressor PTEN, 
while in about 22 % of cases mutations in the histone methyltransferase EZH2 have 
been reported [64].  
Among the genetic aberrations characterizing ABC-DLBCL patients, it is not surprising 
that mutations leading to a chronic activation of both BCR and NFkB signaling 
pathways are very common. In particular, CD79A is mutated in 20 % of ABC-DLBCL 
patients, as well as CD79B, to a lesser extent. Of note, in about 9 % of ABC-DLBCL, 
activation of BCR and NF-κB is sustained by oncogenic mutations of the CARD11 
gene, the major component of the “signalosome” complex [64]. Importantly, also the 
adaptor molecule MYD88, which participates in the signal transduction of most TLRs, 
is affected by gain-of-function mutations in its TIR domain (L265P substitution) in one 
third of ABC-DLBCLs. Least but not last, more or less 25 % of patients have lost 
BLIMP1 due to mutations or deletions of its gene (PRDM1), or because of the 
constitutively active, translocated BCL6 gene [64].  
A further method for classifying DLBCL is based on BCL2 and C-MYC gene 
expression. Specifically, DLBCL are referred as “double hit” lymphomas (DHLs) when 
rearrangements of both genes are present, while in the so called “double expressor” 
lymphoma (DELs) BCL2 and C-MYC are overexpressed at protein level, without 
genetic translocations [73].  




lymphoma, a very aggressive and fast-growing lymphoma, whereas the BCL2-related 
t(14;18) translocation is the genetic hallmark of follicular lymphoma and leads to a 
drug-resistant phenotype with increased cancer cell survival. However, these 
translocations are not specific. Rearrangement of C-MYC also occurs in about 25–30 % 
of DLBCL, whereas that of BCL2 appears in 10-15 % of patients affected by this 
disease. “Double hit” DLBCLs, in which both rearrangements coexist, account for 
approximately 5-7 % of all DLBCL cases and are characterized by a refractory disease 
and short survival [73]. 
“Double expressor” DLBCL, on the other hands, accounting for one third of all DLBCL 
cases, are defined as lymphomas with increased expression of C-MYC and BCL2 
proteins by immunohistochemistry, in the absence of detectable translocation by 
fluorescence in situ hybridization (FISH). They do not form a distinct 
clinicopathological entity in the World Health Organization (WHO) classification, but 
offer additional information about markers associated with a poor outcome. [74].  
Additionally, the two described classifications, the COO-related and the oncogene 
amplification-based, somehow overlap, at least to some extent. Indeed, more DEL have 
gene expression profiles consistent with the activated B-cell subtype of DLBCL, 
whereas most DHLs are GC-DLBCL [73,74].  
 
It is widely recognized that patients with the ABC subtype of DLBCL have 
significantly poorer outcomes to R-CHOP therapy than GC-DLBCL patients [75]. 
Efforts to improve treatment efficacy in patients affected by the ABC disease have been 
made by combining immune-chemotherapy with biologic agents targeting BCR and 
NFkB signaling pathways [76]. Examples are Ibrutinib, an irreversible inhibitor of 
Bruton's Tyrosine Kinase (BTK) belonging to the BCR cascade, and bortezomib, a 
proteasome inhibitor thought to prevent proteosomal degradation of IkB, inhibitor of 
NFkB. 
In cases of relapsed diseases, especially of DHLs, the potent regiment of immune-
chemotherapy R-EPOCH (Rituximab, etoposide, prednisone, vincristine, 
cyclophosphamide, and doxorubicin) is often beneficial and it may also be combined 
with autologous stem cell transplantation (ASCT) [77]. 
A new and more comprehensive understanding of DLBCL molecular aberrations was 
described in 2018 by Schmitz et al., who investigated 574 DLBCL biopsies using 




amplicon resequencing [69]. Interestingly, authors identified four genetic subtypes of 
DLBCL, based on the patient mutational burden: MCD (with the co-occurrence of 
MYD88 L265P and CD79B mutations), BN2 (according to BCL6 fusions and 
NOTCH2 mutations), N1 (with NOTCH1 mutations) and EZB (characterized by EZH2 
mutations and BCL2 translocations).  
 
Figure 5. The mutational burden-based classification of DLBCL [69]. 
 
When combining this mutation-based classification with the classical one based on the 
cell of origin, MCD and N1 were primarily ABC DLBCLs, EZB comprised mostly 
GCB DLBCLs, and BN2 included ABC, GCB, and unclassified cases. Of note, the 
authors were able to better characterize unclassified DLBCL cases (neither GC- nor 
ABC-type). In line with the already described worst prognosis of ABC-DLBCL 
patients, better outcomes were found in the BN2 and EZB subtypes, while poorer 
outcomes in the MCD and N1 subtypes.  
 
1.4 MYD88 and its role in SLE and lymphomas 
 
To detect microbes and self-derived molecules released from damaged cells, the innate 
immune system uses the so-called “pattern-recognition receptors” (PRRs) that 
recognize “pathogen-associated molecular patterns” (PAMPs) and damage-associated 
molecules patterns (DAMPs) [78]. PRRs activate downstream signaling pathways that 
trigger an immediate innate immune response, as well as an antigen-specific adaptive 
immunity. Among the different classes of PRRs, Toll-like receptors were the first to be 




cell surface, others show an intracellular (endosomal) compartmentalization. The TLR 
family includes 10 members (TLR1–TLR10) in human and 12 members (TLR1–TLR9, 
TLR11–TLR13) in mouse. The downstream signaling pathways of most TLRs are 
mediated by the adaptor molecule MYD88 (myeloid differentiation primary response 
88) [79].  
                   
Figure 6. An overview of TLR signaling cascades [79]. 
 
MYD88 structure includes the C-terminal TIR (Toll IL-1R) domain, which mediates the 
interaction with other TIR domain-containing proteins (receptors or adaptors), and the 
N-terminal death domain (DD) that associates with the IRAK family members through 
homotypic DD interactions.  An intermediate (INT) domain links the TIR and DD. 
Except from TLR3, which requires TRIF as scaffold-protein for mediating its signaling, 
MYD88 mediates all TLR signaling cascades.  After TLR engagement, MYD88 forms a 
complex with IRAK kinase family members, referred to as the Myddosome. During 
Myddosome formation, IRAK4 activates IRAK1, which is then autophosphorylated at 
several sites and released from MYD88. IRAK1 associates with the ubiquitin ligase 
TRAF6, that promotes polyubiquitination of both TRAF6 itself and the TAK1 protein 
kinase complex. TAK1 then activates two different pathways that lead to activation of 




phosphorylates the NF-κB inhibitory protein IκBα, which undergoes proteasome 
degradation, allowing NF-κB to translocate into the nucleus to induce proinflammatory 
gene expression. TAK1 also activates MAPK family members such as ERK1/2, p38 and 
JNK, which mediate activation of AP-1 family transcription factors. Among the 
transcribed genes, IL-6, IL1β, TNF-α, and IFN-I are worth noting [79]. 
Also, MYD88 plays a crucial role in physiological B cell response, as it is required for 
antibodies production [80]. More importantly, TLR9-MYD88 axis is highly active in 
the context of SLE, both in humans and mice. Firstly, the endosomal TLR9 recognizes 
unmethylated CpG sequences in DNA molecules, that are massively released by SLE 
patients, as well as by lupus-prone mice. Additionally, TLR9-MYD88 signaling 
promotes autoantibodies class switching to pathogenic IgG2a and 2b in patients [81] 
and lupus-prone mice lacking TLR9 developed a more severe clinical disease [82] [83]. 
As previously mentioned, gain-of-function mutations of MYD88 have been found to 
sustain lymphomagenesis, especially in the ABC type of DLBCL [84]. In particular, 
Staudt’s group reported that 29 % of ABC DLBCL tumours harbored the same amino 
acid substitution, L265P, in the MYD88 TIR domain at an evolutionarily invariant 
residue in its hydrophobic core. MYD88-L265P promoted cell survival by 
spontaneously assembling a protein complex containing IRAKs, thus activating NF-κB 
signaling, JAK/STAT3 pathway and secretion of IL-6, IL-10 and interferon-β. 
Importantly, it has been demonstrated that SYK, a component of the BCR signaling, co-
localizes with MYD88 in MYD88-mutated B cell-lymphomas, driving pro-survival 
signals [85]. 
 
1.5 Blimp1 and human lymphomas 
 
B-lymphocyte-induced maturation protein 1 (BLIMP1) is a transcriptional repressor 
encoded by PR Domain Zinc Finger Protein 1 (PRDM1) gene and its structure includes 
zinc finger DNA-binding domains, a proline-rich region (PR) and an acidic region [86].  
BLIMP1 is essential for the terminal differentiation of B cells into plasma cells, as 
demonstrated by the fact that mice with B cell conditional knockout (KO) of PRDM1 
failed to produce plasma cells and serum immunoglobulins [87]. While during the GC 
stage of B cell development its premature transcription is prevented by BCL6, a master 
regulator of the GC reaction, BLIMP1, in turn, orchestrates plasma cell differentiation 




Among its targets, BLIMP-1 represses c-MYC, which explains the cessation of cell 
cycle in plasma cells, the MHC class II transactivator CIITA, leading to a 
downregulation of MHC-II in plasma cells, and PAX5, which is required for CSR in 
GCs. 
Interestingly, the expression of BLIMP1 is known to be induced by MYD88-related 
pathways, as LPS-stimulated B cells from MYD88-/- mice show decreased expression 
levels of PRDM1 [89]. In line with this, BLIMP1 is transcriptionally regulated by 
NFkB [90]. Furthermore, BLIMP1 is a well-known target of STAT3 signaling pathway 
[91]. 
BLIMP1 is inactivated at gene level in nearly 25 % of ABC-DLBCL patients, who 
harbor PRDM1 homozygous deletions, truncating or missense mutations. However, 
BLIMP1 could be also transcriptionally repressed by constitutively active BCL6 [92]. 
Furthermore, in vivo, conditional deletion of Blimp1 in mouse B cells promotes the 
development of lymphoproliferative disorders recapitulating critical features of the 
human ABC-DLBCL.  In light of all these findings, BLIMP1 may be referred as a 
tumor suppressor and indeed its absence correlates with the upregulation of genes 
involved in B cell receptor signaling and cell proliferation (i.e. C-MYC), and with the 
poor prognosis of ABC-DLBCL patients [93].  
Surprisingly, BLIMP1 expression was reported in a sizable fraction of DLBCL, which 
displayed more aggressive behavior and shorter failure-free survival [94]. These tumors, 
however, co-expressed BCL-6 and MUM1/IRF4, confirming that PRDM1 expression 
was insufficient to drive the full genetic program associated with plasmacytic 
differentiation. 
A further study investigated PRDM1 transcript variants in 82 DLBCL patients [95]. 
PRDM1 has two isoforms: PRDM1α and PRDM1β, generated from the same gene by 
alternative transcription. PRDM1β differs from PRDM1α by lacking the N-terminal 101 
amino acids and having a disrupted PR domain, thus losing repressive function on 
multiple target genes. Notably, using laser micro-dissection combined with reverse 
transcription–polymerase chain reaction (RT-PCR) amplification, the authors found that 
both PRDM1α and PRDM1β transcripts were expressed in lymphoma cells only in the 
non-GC subtype of DLBCL. Of note, PRDM1β was correlated with short survival in 
non-GC patients treated with CHOP but not with R-CHOP. Indeed, in vitro, B 
lymphoma cells resistant to chemotherapy expressed PRDM1β, that was suppressed 







Osteopontin (OPN) is a glycosylated phosphoprotein that is expressed in a variety of 
cells, namely macrophages, neutrophils, dendritic cells, NK cells, T and B lymphocytes, 
as well as epithelial cells and fibroblasts [96]. It was originally identified as a bone 
matrix protein and subsequently identified as a cytokine (Eta-1) produced by activated 
T cells and transformed cell lines [96]. Additionally, OPN is a significant component of 
the extracellular matrix (ECM), where it interacts with specific elements including 
collagen, fibronectin and calcium (due to its Ca2+ binding sequence), thereby 
regulating matrix interactions and cell adhesion [97]. 
OPN is able to interact with ubiquitously expressed multiple cell surface receptors that 
mediate many physiological and pathological processes. Among these, OPN promotes 
cell survival, inflammation, adhesion, migration and, more generally, it has been 
associated with bone formation, wound healing, autoimmune disorders and 
tumorigenesis.  
 
1.6.1 Osteopontin structure 
 
OPN is a highly negatively charged protein lacking extensive secondary structure and it 
belongs to the SIBLING (Small Integrin-Binding Ligand, N-linked Glycoprotein) 
family. It is encoded by SPP1 gene, located on chromosome 4 in humans and 5 in mice. 
OPN is a 33kDa protein, being composed by more or less 300 amino acids. However, a 
wide range of post-translational modifications, including phosphorylation, O-linked 
glycosylation, sulfation and sialylation, increase its molecular weight to around 44Kda 
[96].  
Near the center of OPN sequence there is an arginine-glycine-aspartate (RGD) domain, 
a motif common to many extracellular matrix proteins and known to engage several 
integrins. OPN also contains an aspartate-rich region, two heparin-binding sites, 
proteolytic cleavage sites for thrombin and metalloproteinases, and, near the C-
terminus, a region that binds CD44 [96]. Via the RGD sequence, OPN interacts with a 
variety of integrins, including αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 [98]. The thrombin-
mediated cleavage of OPN allows the exposure of a cryptic integrin binding site 
(SVVYGLR in human, SLAYGLR in mouse). The N-terminal fragment of OPN has 




promoting the adherence of cells, mostly leukocytes, expressing α4β7 and α9β1 
integrins. 
Furthermore, OPN interacts with two specific variants of the receptor CD44, namely v6 
and v7, mediating a loop which stimulates its own transcription and accumulation of the 
protein on the cell surface [96].  
          
Figure 7. Osteopontin structure [96]. 
 
1.6.2 The secreted and the intracellular isoforms of OPN  
 
OPN has always been studied as a secreted protein (sOPN), as it is released by the 
expressing cells into body fluids. However, recently it has been identified in mouse an 
intracellular isoform of the protein (iOPN), firstly described by Sodek’s group in rat 
calvarial cells [99]. Using confocal microscopy, the authors found two patterns of OPN 
distribution: a perinuclear (Golgi reticulum) for sOPN, and a perimembrane distribution 
for iOPN. Surprisingly, iOPN was also found in cytoplasm [100] as well as in the 
nucleus, being associated to MYD88 [101] or BCL6 [102]. 
Importantly, the intracellular isoform of OPN does not derive from an alternative 
splicing of Spp1 gene. Indeed, iOPN differs from sOPN because of its non-AUG 
translation start site, located downstream that of the full-length protein. Thus, in the 
structure of iOPN the sequence leading to the secretory vesicles is missing, so that cells 







Figure 8. The secreted and the intracellular isoform of OPN [103]. 
 
Additionally, iOPN exists as an integral component of a CD44-ezrin/radixin/moesin 
(ERM) complex located in the internal region of the plasmatic membrane, being a 
player in cell motility and fusion [103].  
The sOPN-integrin axis promotes NFkB activation via Ras and Src [104]. NFkB, on the 
other hand, regulates the expression of many inflammatory cytokines, including OPN 
[105]. Additionally, CD44 engagement by OPN mediates the activation of 
PI3K/AKT/β-catenin pathway [106] [107], that, in turns, promotes the transcription of 
SPP1 gene. 
Also, iOPN not only functions as an adaptor or scaffold protein in signal transduction 
pathways, but also stabilizes other intracellular proteins. Indeed, in T follicular helper 
and T follicular regulatory cells, Cantor’s group discovered an ICOS-mediated 
interaction between p85α regulatory subunit of PI3K and iOPN, followed by nuclear 
translocation of the latter, its interaction with Bcl-6 and protection of Bcl-6 from 
ubiquitin-dependent proteasome degradation [102]. Interestingly, the co-localization of 
iOPN and the scaffold protein Myd88 has been described in different cell types and 
contexts, but with contradictory results: while iOPN was found to promote TLR9-
mediated IFN-α production in plasmacitoid dendritic cells [108], overexpression of 
iOPN in OPN-deficient macrophages strongly suppressed production of NFkB-
transcribed pro-inflammatory cytokines after stimulation with cellular debris [101]. 
Moreover, iOPN interacts with and stabilizes TRAF3, adaptor molecule belonging to 
the TLR3 signaling cascade, thus promoting IRF3 activation, IFN-β production and 





1.6.3 OPN regulation 
 
As previously mentioned, OPN expression is promoted by several pathways [110], 
mostly oncogenic, namely NFkB, PI3K/AKT/β-catenin, Hedgehog and estrogen 
receptor (ER) signaling cascade. Indeed, Ramchandani and Weber discovered a 
polymorphic site, in position −443 of the SPP1 promoter, that showed differences 
between ER-positive and ER-negative breast cancers [111].  
Among the several cis-regulatory elements identified in SPP1 promoter, a Ras-activated 
enhancer (RAE) is bound by Ras-response factor (RRF), when Ras signaling pathway is 
stimulated [110]. Furthermore, T cell factor-4 (Tcf-4) binds the Tcf-4 binding site, 
retarding OPN transcription [110]. Additionally, the −94 to −24 region of the human 
SPP1 promoter is able to bind a variety of known transcription factors, including Sp1, 
Myc and Oct-1 [110].  
On the other hand, to counteract OPN expression, there are many repressors that 
negatively regulate its transcription, for example Breast cancer metastasis suppressor 1 
(BRMS1), the transcriptional repressor RUNX3, and wild type BRCA1, that acts by 
impounding OPN trans-activators [110].  
 
1.6.4 OPN functions 
 
Although sOPN and iOPN recognize and bind different partners, thus promoting 
distinct pathways, both isoforms participate in immune-related processes, and, in some 
cases, their functions are overlapping and synergistic. 
OPN main immune-modulatory function is the enhancement of Th1 over Th2 immunity 
through two general mechanisms. Specifically, while the N-terminal region of OPN 
interacts with the αvβ3 integrin to induce pro-inflammatory IL-12, the C-terminal 
sequence of the protein binds to CD44, leading to the suppression of the anti-
inflammatory cytokine IL-10 [112]. Furthermore, among CD4+ T cells, Spp1 mRNA is 
expressed in Th1, but not in Th2 subset [113], and this is in line with the notion that 
OPN gene expression in activated T cells is regulated by T-bet, a transcription factor 
important tor T cell commitment [114].  
As concerns the role of OPN in B cells, in the 90’s Cantor’s group demonstrated that 
OPN is important for B cell activation and antibody production in MRL/lpr mice [115]. 
Additionally, the involvement of OPN in B cell development was also demonstrated by 




and lymph nodes in a model of imiquimod-induced psoriasis  [116]. 
Importantly, Benchang Guo et al. reported that OPN expression in B cells is regulated 
by both the classical BCR signaling (PI3K-, phospholipase C- and PKCβ-dependent) 
and the non-classical, IL4-triggered, BCR cascade (Lyn-dependent). Going deeply, 
while stimulating the canonical BCR signaling with anti-Ig did not increase the level of 
Spp1/OPN in murine B cells, [117], triggering both the canonical and non canonical 
BCR cascades with anti-Ig and IL4, respectively, allowed follicular B and marginal 
zone B cells to express and secrete OPN.   
 
OPN activity, specifically mediated by its N-terminal fragment, has been described also 
in the regulation of the hematopoietic stem cell niche in which OPN expression is 
restricted to the endosteal region of the bone marrow and exterts a negative role on 
hematopoietic stem cell proliferation [118]. 
Interestingly, a study from Shinohara’s group reported that, upon Candida infection or T 
cell-mediated colitis, sOPN and iOPN exert different role in skewing myeloid versus 
lymphoid population balance in the bone marrow [119]. Specifically, iOPN was able to 
promote apoptosis through the downregulation of survivin expression and the 
enhancement of pan-caspase activities in myeloid progenitors, while sOPN increased 
the population size of lymphoid cells.  
Remarkably, phagocytic cells produce high levels of OPN mRNA but do not secrete 
OPN as much as activate T cells do, tending to store OPN in the cells [113].   
Overall, based on the reported literature it seems that sOPN and iOPN participate 
mainly in adoptive and innate immunity, respectively. 
 
1.6.5 OPN and autoimmune disorders 
 
In line with its role in promoting inflammatory responses, the detrimental role of OPN 
in mediating a wide range of autoimmune diseases has long been described [120].  
In patients affected by SLE, for example, OPN is a cytokine massively secreted in the 
blood and its abundance correlates with disease severity and poor outcome [121]. 
Indeed, high OPN levels are associated with the presence of autoantibodies against 
nucleic acids, elevated IFN-α levels in the serum and renal damage [122]. The 
relationship between OPN and SLE has also been confirmed at genetic level, since OPN 
polymorphisms are associated with specific clinical features of the disease, such as 




lymphadenopathy, high serum levels of IgE and IFN-α [123] [124]. Notably, also the 
lupus-prone MRLlpr/lpr mice, show an high secretion of OPN, that begins at the onset 
of autoimmunity and positively correlates with the symptom severity [125], which is 
also influenced by polymorphisms in OPN gene  [126]. Also, Ciocchetti et al. proposed 
that OPN may contribute to the disease by inhibiting lymphocyte apoptosis, worsening 
the mutation-driven Fas defect [127]. Interestingly, Weber and Cantor highlighted a 
dual and opposite role of OPN during the progression of the disease in mice with the lpr 
mutation [128]. At early stages, OPN induces polyclonal B cell activation and isotype 
switching, leading to IgG, IgM and IgA production, thereby sustaining the pathology. 
On the contrary, during the late phases, OPN prevents further exacerbation of the 
disease by inhibiting the production of Th2 cytokines IL-10 and IL-4 [96]. 
In multiple sclerosis (MS) OPN is one of the most prominent cytokines expressed 
within lesions (especially during relapses), blood and cerebrospinal fluid of patients. In 
particular, the thrombin- and metalloproteinase-cleaved OPN fragments play a crucial 
role in mediating the recruitment of autoimmune T cells in MS lesions. In addition, 
genetic analyses have associated variations of the OPN gene with the disease as well 
[120]. In the mouse model of MS, the experimental autoimmune encephalomyelitis 
(EAE), where the pathology is mediated by myelin specific autoreactive T cells, 
administration of OPN to OPN-deficient mice worsened the disease by inducing relapse 
and neurological defects [96]. 
As a further illustration, rheumatoid arthritis (RA) is a chronic autoimmune disease 
characterized by an inflammatory attack of the joint space, site where several cytokines 
are highly expressed, including OPN, together with IL-1 and TNF-α [120]. Moreover, 
high levels of OPN have been reported in the peripheral blood of RA patients and have 
been associated with disease severity [120]. Importantly, OPN transcript is strongly 
expressed in CD4+ synovial T cells and correlates with co-expression of certain OPN 
receptors, including αv and β1 integrin chains and CD44. Although some studies did not 
find any association between OPN polymorphisms and susceptibility to RA, Ceccarelli 
et al. discovered a correlation between a specific SNP in the SPP1 promoter and the 
susceptibility to the disease [129]. As demonstrated in the collagen-induced arthritis 
(CIA) model of RA, OPN recruits inflammatory cells to arthritic joints. Indeed, 
treatment of arthritic mice with an antibody against the SLAYGLR sequence, exposed 
after thrombin-mediated cleavage of OPN, decreased immune cell infiltration at the 




1.6.6 OPN and cancers 
 
If OPN plays beneficial roles in physiological processes like wound healing, bone 
homeostasis, and ECM functions, OPN is a cardinal mediator of tumor-associated 
inflammation and metastatic dissemination. Indeed, OPN has been widely implicated in 
the development and progression of several types of cancer and, in most cases, high 
expression levels of OPN or its specific isoforms are associated with poor prognosis 
[96] [131].  
Indeed, several studies have demonstrated the correlation between elevated OPN 
secretion and advanced tumor stage in breast cancer, prostate cancer, squamous cell 
carcinoma, melanoma, osteosarcoma and gliobastoma [110,131]. Other than mediating 
the previously described signaling pathways that promote cell survival and 
proliferation, OPN exerts a crucial role in a wide range of processes referred as 




Figure 9. The association between OPN and the hallmarks of cancer [110]. 
 
As far as angiogenesis is concerned, one of the described mechanisms involving OPN 
relies on its high affinity for αvβ3, whose cascade is essential for endothelial cell 
survival. Also the association between OPN and cancer metastasis has been studied in 
several types of cancer, such as melanoma, colorectal and lung cancer [119, 131]. 
Notably, through an approach consisting in Spp1 silencing in the 4T1 breast cancer cell 
line and the use of OPN-deficient mice, Sangaletti et al. found that tumor-intrinsic OPN 
protects breast cancer cells from apoptosis within the blood stream (anoikis), whereas 
myeloid cell-derived OPN, likely in its intracellular form, regulates their 




Epithelial-to-Mesenchymal Transition (EMT), the process in which epithelial cells 
revert back to their mesenchymal phenotype, is a further hallmark of cancer OPN has 
been associated with. There are three main types of EMT: type 1 refers to 
embryogenesis, type 2 is related to wound healing, and type 3 concerns cancer 
metastasis. OPN has been shown to play a crucial role in mediating type 2 and 3 EMT, 
the latter mainly in breast, hepatocellular carcinoma and colorectal cancer [131]. In 
particular, OPN can directly regulate the expression of EMT-related transcription 
factors including Twist, Snail and Slug. Furthermore, OPN is able also to indirectly 
activate Twist via hypoxia-inducible factor-1 alpha (HIF-1α), thus enhancing cell 
migration and invasion. 
In addition, autophagy, the catabolic process occurring in stress conditions and in which 
cellular organelles are degraded by lysosomes, has been shown to promote chemo-
resistance in some cancers. Remarkably, OPN was found to promote resistance to 
chemotherapeutic agents in pancreatic cancer, hepatocellular carcinoma and breast 
cancer by inducing NFkB, integrin αvβ3/MEK/ERK and PI3K/AKT pathways, 
respectively [131]. 
In line with all these findings, it is not surprising that the current research indicates that 
OPN inhibition would be a good therapeutic approach, particularly in a context of 
metastatic diseases [133]. Indeed, an increasing body of literature exploited the 
application of OPN inhibition in different cancers and experimental settings. In 
particular, small interfering RNA (siRNA) and short hairpin RNAs (shRNAs) against 
OPN showed high stability, resistance to immunogenicity and high efficacy in low dose 
[133]. Moreover, also the efficacy of molecules like aptamers and antibodies, both 
aimed at disrupting OPN binding to its receptor CD44 and integrins, was evaluated as a 
potential therapeutic strategy. 
 
1.6.7 Human OPN splicing variants 
 
In human, OPN precursor-mRNA (pre-mRNA) is subject to alternative splicing, which 
generates three splice variants, OPN-a (consists of all seven exons), OPN-b (which 
lacks exon 5) and OPN-c (which lacks exon 4). Since the expression of OPN splice 
variants in malignancies is cell-type and/or tissue specific, this may influence the 
potential role of OPN in distinct tumours and as cancer biomarker [134]. However, 




isoforms in different solid tumours. A variety of studies are in agreement with the 
notion that OPN-c is the variant mainly expressed in malignant tissues rather than the 
healthy ones. As an example, OPN-c was found to be selectively expressed in breast 
cancer tissue and to be inversely correlated with E-cadherin, an established tumour 
suppressor. Moreover, high levels of OPN-c staining in breast tumours are associated 
with tumour stage, recurrence and metastasis [134]. Additionally, it has been shown that 
OPN-c supports anchorage-independent growth via the expression of oxidoreductases 
[134]. 
On the other hand, it has been demonstrated that hepatocellular carcinoma tissues 
predominantly expressed OPN-a and OPN-b rather than OPN-c. In line with this work, 
OPN-a was found to be the most expressed isoform in lung cancer biopsies and cell 
lines [135]. Functionally, the authors described how OPN-a promotes angiogenesis by 
stimulating endothelial cells, likely by binding to the αvβ3 integrin and increasing 
VEGF expression and secretion.  
 
1.6.8. OPN and hematological malignancies 
 
While OPN functions have been deeply explored in the context of solid tumours, less is 
known about its contribution to lymphoid malignancies. Generally speaking, OPN was 
found to be highly expressed in hematological diseases, such as primary central nervous 
system lymphomas (PCNSL, a DLBCL confined to the CNS) and in bone marrow 
blasts of acute myeloid leukemia (AML) patients [136,137]. As concerns PCNSL, SPP1 
gene was found to have a 10-fold increase in PCNSLs when compared to non-CNS 
DLBCLs [136]. Furthermore, OPN overexpression was also been reported in an 
aggressive subset of DLBCL characterized by a poor outcome [136]. From a pathogenic 
point of view, OPN was found to mediate invasion and dissemination of CNS 
lymphomas through the activation of metalloproteinases (MMP) via NFkB [136]. 
Notably, Rolf Mesters’ study described how OPN is overexpressed in the bone marrow 
of AML patients compared with healthy individuals, and more importantly, that the 
protein is an independent prognostic marker in this disease [137]. In addition, OPN has 
also been involved in resistance to chemotherapy in acute lymphoblastic leukemia 
(ALL), since Boyerinas et al. demonstrated that stroma-derived protein, when localized 
to the endosteal region of the bone marrow, was able to adhere to ALL clones 




Taken together, these findings indicate that OPN not only represents a potential 
biomarker for several lymphoproliferative diseases, but also exerts multifaceted roles in 





2. AIM OF THE STUDY 
 
While OPN is widely described as a pro-inflammatory and pro-tumorigenic molecule, 
involved in the pathogenesis of autoimmune disorders and solid tumours, the role of this 
protein in B cell malignancies is poorly described.  
The aims of my PhD project are: 
-Deciphering the role of OPN in lymphoma development associated with an 
autoimmune condition (mice prone to develop a SLE-like syndrome) and investigating 
whether a specific isoform of the protein (soluble vs intracellular OPN) is relevant in 
this process. 
-Investigating B cell-intrinsic and stromal-related dynamics at the basis of the 
autoimmunity-driven malignancy, also taking advantage from engineered cell lines and 
OPN+/+ and OPN-/- hosts.  
-Translating the findings obtained with the spontaneous mouse model in the human 









BALB/c mice were purchased from Charles River Laboratories. C57BL/6 spp1-/- mice 
(B6.129S6(Cg)-Spp1tm1Blh/J were purchased from the Jackson laboratory and 
backcrossed on BALB/c background for 10 generations, obtaining BALB/c;Spp1tm1Blh 
animals [132]. MRL/MpJ-Faslpr/J mice were originally purchased from the Jackson 
Laboratory and crossed with BALB/c mice for 10 generations to obtain 
BALB/c;Tnfrsf6lpr strain (referred as Faslpr/lpr). Faslpr/lpr mice were crossed with 
BALB/c;Spp1tm1Blh, obtaining OPN-/-Faslpr/lpr animals (BALB/c;Spp1tm1Blh x 
Tnfrsf6lpr). Only female mice were used for this study. Animals were maintained in 
pathogen-free conditions in our animal facility. Autoimmune mice (Faslpr/lpr and OPN-/-
Faslpr/lpr) were sacrificed for autoimmunity and lymphoma analyses between 4 and 6 
months. Immunodeficient CNCr-Foxn1nu mice (nu/nu) were maintained and crossed at the 
Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy). All animal experiments 
were approved by the Institutional Ethics Committee for Animal Use and by the Italian 
Ministry of Health (authorization number 1026/2016-PR and 419/2021-PR) and were 
performed following to the 3Rs’ recommendations (Reduction, Refinement and 
Replacement). 
3.2 Cell lines 
 
The lymphoma cell lines OPL239 and OPL241 were established in our laboratory by in 
vitro seeding of cell suspension from the lymphomatous spleens of two 6-month-old 
OPN-/-Faslpr/lpr mice. Cell lines were cultured in RPMI-1640 (Lonza, #12-115F), 
supplemented with 10% FBS (Euroclone, #ECS0180L), non-essential amminoacid 
(NEAA) mixture (Lonza, #13-114E), Hepes (Lonza, #17-737E), Na pyruvate (Lonza, 
#BE13-115E) and 51 µM β-mercaptoethanol (Sigma, #M7522).   
 
3.3 Evaluation of autoimmunity in Faslpr/lpr and OPN-/-Faslpr/lpr mice 
 
Swelling of neck, axillary and inguinal lymph nodes was evaluated using a caliper. Both 
the number and the volume (mm3) were considered for the analysis. The percentage of 




spleen and blood samples. Histopathological evaluation of spleen architecture was 
performed by a pathologist. 
 
3.4 ELISA on mice sera 
 
The serum was isolated from the blood through a thermal shock (incubation at 37 °C for 
30 min and at 4 °C for 1 h) followed by a centrifugation at 13000 rpm for 1 min.  
Supernatants (sera) were stored at -20 °C. ELISA on sera was performed to test the 
amount of autoantibodies against circulating self ssDNA (Società Italiana Chimici, 
#5310) and dsDNA (Società Italiana Chimici, #5110), using pre-coated plates. To 
evaluate the serum level of OPN in OPN-sufficient mice, the DuoSet kit for mouse 
Osteopontin (R&D System, #DY441) was used. 
 
3.5 Evaluation of lymphoma by histopathology  
 
Autoimmune mice were sacrificed at 4-6 months of age and hematoxylin and eosin 
staining was performed on formalin-fixed paraffin-embedded (FFPE) spleen sections to 
evaluate the presence of lymphomatous cells. Histopathological analyses were 
performed according to the criteria for lymphoid neoplasm classification by the 
pathologist [139]. 
 
3.6 Flow cytometry 
 
To identify and phenotypically characterize splenic B cells, mouse spleens were 
mechanically disaggregated using the bottom of a syringe, treated with ACK 
(Ammonium-Chloride-Potassium) solution to lyse red blood cells and cell suspensions 
were stained with the following monoclonal antibodies:  
Marker Fluorochrome Company Clone Catalogue n° 
CD19 FITC BD CL1D3 557398 
B220 PE BD RA3-6B2 561868 
IgM PE-Cy7 eBioscience Eb121-15f9 25-5890-82 
CD3 APC eBioscience 145-2c11 17-0031-82 
TLR9 FITC eBioscience M9.D6 11-909382 
CD86 PE eBioscience GL1 12-0862-82 






To discriminate the different splenic B cell populations, mouse spleens disaggregated as 
described were stained with the following monoclonal antibodies:  
Marker Fluorochrome Company Clone Catalogue n° 
IgD FITC eBioscience 11-26c 11-5993-82 
CD23  PE eBioscience B3B4 12-0232-82 
CD21/35 PerCP-Cy5.5 BioLegend 7E9 123416 
CD93  APC eBioscience AA4.1 17-5892-82 
CD19 APC-eFluor780 eBioscience Eb101D3 47-0193-82 
CD3 BV510 BD 145-2c11 563024 
 
Spleens from BALB/c, OPN -/-, Faslpr/lpr and OPN-/-Faslpr/lpr, as well as spleens from 
mice injected with DLBCL cell lines, were also analysed for the presence of the 
different immune cell populations, besides B cells, using antibodies against specific cell 
markers.  
For myeloid cells, the following mixture was used: 
Marker Fluorochrome Company Clone Catalogue n° 
CD11c FITC eBioscience N418 11-0114-85 
CD11b  PE TONBO M170 50-0112-U100 
CD3 PerCP-Cy5.5 TONBO 145-2c11 65-0031-U100 
F4/80 PE-Cy7 BioLegend BM8 123114 
B220 APC eBioscience RA3-6B2 17-0452-82 
LY-6C BV421 BD AL21 562727 
GR-1 BV510 BD RB6-8C5 563040 
 
For lymphoid cells, the following antibodies were used: 
Marker Fluorochrome Company Clone Catalogue n° 
CD25 FITC BioLegend 3C7 101908 
CD8 PE TONBO 2.43 50-1886-U025 
FOXP3  PerCP-Cy5.5 eBioscience FJK-165 45-5773-82 
CD3 BV510 BD 145-2c11 563024 
CD4  BV650 BD RM4-4 740-446 
CD3  FITC eBioscience 145-2c11 11-0031-82 
CD8 PE-Cy7 TONBO 2.43 60-1886-U100 
Ki67 APC BioLegend 16A8 652405 
TIM-3 BV421 BD 5D12/TIM3 747026 





To assess the phenotype of DLBCL cell lines, cells were stained with the following 
antibodies: 
Marker Fluorochrome Company Clone Catalogue n° 
CD19 FITC BD CL1D3 557398 
B220 PE BD RA3-6B2 561868 
IgM  PE-Cy7 eBioscience Eb121-15f9 25-5890-82 
TLR9 FITC eBioscience M9.D6 11-909382 
IgD BV510 BD 11-26c.2A 563110 
IgA FITC BD c10-3 559354 
CXCR4 PerCP-efluor710 eBioscience 2B11 46-9991-82 
 
Samples were acquired on a LSRFortessa flow cytometer (BD) and analysed using 
FlowJo software. 
 
3.7 Immunohistochemistry and immunofluorescence on murine and 
human tissues 
 
Tissues were collected for fixation in 10% neutral buffered formalin overnight, washed 
in distilled water and paraffin-embedded. Four-micrometers-thick sections were 
deparaffinized, rehydrated and unmasked using Novocastra Epitope Retrieval Solutions, 
either pH6 (Leica Biosystem, #RE7113-CE), or pH9 (Leica Biosystem, #RE7119-CE) 
in thermostatic bath at 98°C for 30 minutes. Subsequently, the sections were brought to 
room temperature and washed in PBS. After that, slides underwent neutralization of the 
endogenous peroxidase with Novocastra Peroxidase Block (Leica Biosystems, 
#RE7101), and Fc bloking with Novocastra protein block (Leica Biosystems, 
#RE7102). Then, samples were incubated with primary antibodies. For multiple-marker 
immunostainings, sections were subjected to sequential rounds of single-marker 
staining and the binding of the primary antibodies was revealed by the use of specific 
secondary antibodies conjugated with different fluorophores or enzymes. 
The following primary antibodies were adopted for IHC and IF: 
Antibody Company Clone Catalogue n° 
Rat α-BCL6 Abcam 7D1 ab243150 
Rabbit α-c-MYC Abcam Y69 ab32072 
Rabbit α-CD4 CST* D7D2Z 25229 
Rabbit α-CD8α CST D4W2Z 98941 




Rabbit α-Ki67 Abcam Polyclonal ab15580 
Rabbit α-MPO  Abcam Polyclonal ab9535 
Rabbit α-OPN Abcam EPR21138 ab218237 











CST*: Cell Signaling Technologies  
 
After incubation with HRP-conjugated IgG (H&L) specific secondary antibodies (Life 
Technologies), signals were revealed with Novocastra DAB Chromogen (Leica 
Biosystems, #RE7105) in its Novocastra DAB Substrate Buffer (Leica Biosystems, 
#RE7106). 
Double immunohistochemical staining was performed by applying SignalStain®Boost 
IHC Detection rabbit alkaline phosphatase-conjugated (Cell signaling technology, 
#18653) and Vulcan Fast Red chromogen kit (Bio-optica, #FR805M) as substrate-
chromogens.  
Anti-mouse and anti-rabbit Alexa Fluor 488- and 568-conjugated secondary antibodies 
were used for fluorescence detection.  
At least 5 human samples per group were used. Slides were analyzed under a Zeiss 
Axioscope A1 microscope equipped with four fluorescence channels widefield IF. 
Microphotographs were collected using a Zeiss Axiocam 503 Color digital camera with 
the Zen 2.0 Software (Zeiss). Slide digitalization was performed using an Aperio CS2 
digital scanner (Leica Biosystems) with the ImageScope software.  
 
3.8 Gene Expression Profile on mouse CD19+ cells 
 
We collected spleens from 5-month-old Faslpr/lpr mice (without signs of lymphoma), 5-
month-old OPN-/-Faslpr/lpr mice (that showed initial lymphomatous foci) and the few 8 
month-old Faslpr/lpr and OPN-/-Faslpr/lpr mice (both showing an overt lymphoma) that 
were able to survive that far. As controls, we collected also spleens from 5-month-old 
BALB/c and OPN -/- mice. CD19+ cells were purified through immunomagnetic beads 
anti-CD19 (Miltenyi, #130-121-301). 5 mice per group were used for this experiment. 
RNA extraction was performed using Quick-RNA Microprep (Zymoresearch, #R1051) 
and its purity and yield were assessed using NanoDrop 2000c spectrophotometer 




through Agilent Technologies Scanner G2505C US11103886 by the Functional 
Genomics core facility at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. 
Raw data were imported in R software through read.maimages function from limma 
packages. Data were normalized through normalizeBetweenArrays function from 
limma package with method cyclicloess. Filtering and collapse were applied on probes, 
in particular the 95% percentile of the negative control probes was computed on each 
array. Probes that were at least 10% brighter than the negative controls on at least 5% of 
arrays were kept. Average expression of replicated probes were computed and then 
collapse with collapseRows function from WGCNA package (with method 
maxRowVariance) was performed. Class comparison was performed through limma 
package from Bioconductor for each pair of comparison, and p-value was corrected 
through Benjamini and Hockeberg method (BH). Pathway analysis was made through 
package pathfindR with REACTOME database with genes that were resulted significant 
(FDR < 0.05) from the previously described class comparison.  
 
3.9 RNA SCOPE 
 
RNA scope on fresh murine spleen sections was performed using RNAscope 2.5 HD 
Detection Reagent-BROWN (Advanced Cell Diagnostic) in accordance with the 
manufacturer’s protocol. Mouse Prdm1 (#441871) was used as probe.  
Novocastra DAB Chromogen (Leica Biosystems, #RE7105) in its Novocastra DAB 




RNA extraction was performed using Quick-RNA Microprep (Zymoresearch, #R1051) 
and its purity and yield were assessed using NanoDrop 2000c spectrophotometer 
(Thermofisher Scientific). RNA was reverse transcribed using High Capacity cDNA 
Reverse Transcription Kit (Thermofisher, #4368814); the 20 µl reaction for RT-qPCR 
was prepeared using TaqMan Fast Universal PCR Master Mix no Amperase UNG 
(Thermofisher, #4352042) and run on a QuantStudio 3 instrument (Thermofisher). 
Primers and probes were synthesized by IDT or Applied Biosystems (AB). 





Gene name Company ID probe 
Gapdh IDT Mm.PT.39.a1 
Bcl2 IDT Mm.PT.58.7362966 
Bcl6 IDT Mm.PT.58.32669842 
c-myc IDT Mm.PT.58.13590978 
Irf4 IDT Mm.PT.58.31041885 
Spp1 IDT Mm.PT.58.43709208 
Gapdh AB Mm99999915_91 
Il6 AB Mm00446190_m1 
Prdm1 AB Mm00476128_m1 
Tnf6f13b (Baff) AB Mm_00446347_m1 
Tnfα AB Mm00443258_m1 
 
Gene expression levels were normalized through the comparison with mouse Gapdh 
expression. The expression values are referred as 2-ΔCT. 
 
3.11 Evaluation of MYD88 signaling pathway in mouse CD19+ cells 
and DLBCL cell lines 
 
CD19+ cells were isolated from mouse spleens using Microbeads anti-CD19+ 
(Miltenyi, #130-121-301) and the purity of cells was assessed by flow cytometry using 
an antibody against CD19 (CD19 FITC (BD, clone CL1D3, #557398). For western blot 
analysis, 2x106 cells were seeded in 6-well plates and stimulated for 1h. For flow 
cytometry analysis and RT-qPCR 1x106 cells were seeded in 12-well plates and 
stimulated for 3 days. The following TLR agonists were used: the TLR4 agonist LPS 
(Lipopolysaccharides from Escherichia coli O111:B4, Sigma, #L4130) (1 µg/ml), the 
TLR9 agonist CpG 1826 (TriLink Biotechnologies, #I66-G01A) (5 µg/ml), the TLR3 
agonist Poly I:C (Polycytidylic-inosinic acid potassium salt, Sigma, #P1038) (5 µg/ml). 
After stimulation cells were collected and washed in PBS. Dry pellets were stored at -80 
°C for western blot analysis, while fresh samples were stained with the different 
antibodies for flow cytometry analysis of activation (CD19 FITC, BD, clone CL1D3, 
#557398 and CD86 PE, eBioscience, clone GL1, #12-0862-82).  
To evaluate TLR9-MYD88 cascade in OPL239/OPL241 DLBCL cell lines, 1,5 x106 
cells were seeded in 6-well plates and stimulated with 5 µg/ml CpG (TriLink 




Then, cells were washed in PBS and dry pellet were stored at -80°C for Western Blot 
and RT-PCR analysis. 
 
3.12 Western blot analysis 
 
Cells were lysed in ice for 20 min using RIPA buffer, added with phosphatase 
(Phosphostop, Roche, #04906837001) and protease (Complete, #11836153001) 
inhibitor cocktails, and 1mM PMSF. Lysates were then centrifuged at 13000 rpm for 20 
min and the supernatants containing proteins were stored at -80°C. Proteins were 
quantified through Pierce BCA Protein Assay Kit (Thermofisher, #23225) and optical 
density evaluated by Spark Multimode microplate reader. An equal amount of proteins 
(20 µg) was run on SDS-PAGE on NuPAGE 4-12% pre-casted minigels (Invitrogen, 
#NP0321BOX) and proteins were transferred to 0.45µm nitrocellulose membrane 
(Amersham, #10600002). Nonspecific binding sites were blocked in PBS containing 0.1 
% Tween 20 (Sigma, #P2287-500ML) and 5 % BSA (Sigma, #A7906-100G). 
Membranes were incubated overnight at 4 °C with the following antibodies: 
Antibody Company Clone Catalogue n° 
Rabbit α-β-ACTIN Sigma A2066 090M4758 
Rabbit α-BCL2 CST* D17C4 34985 
Rabbit α-c-MYC CST D84C12 56055 
Rabbit α-IRAK1 CST D51G7 45045 
Rabbit α-IRAK4 CST Polyclonal 43635 
Rabbit α-IRF4/MUM1 Abcam Polyclonal ab104803 
Rabbit α-MYD88 Abcam Polyclonal Ab2064 
Goat α-OPN Sigma Polyclonal 07635-1MG 
Rabbit α-ph-p65 
(Ser536) 
CST 93H1 3033 
Rabbit α-p65 CST D14E12 #82426 
Rabbit α-ph-STAT3 
(Y705) 
CST D3A7 #91456 
Rabbit α-STAT3 CST 79D7  4904T 
*CST: Cell Signaling Technologies 
 
After incubation, membranes were washed three times, for 10 min each, in PBS 
containing 0.1 % Tween 20, and then incubated for 30 min at room temperature with 
the following secondary antibodies: Rabbit anti-goat (Invitrogen, #811620) and Donkey 




After washing, blots were developed with Clarity Western ECL Substrate (Biorad, 
#1705061) and images were acquired using Chemidoc XRS system (Biorad).  
Quantification was made with ImageJ64.  
 
3.13 Sorting of immune populations from mouse spleens 
 
To assess Spp1, Tnfsf13b and Il6 expression in the different immnune populations, 
spleens from 3/4-month-old BALB/c, OPN-/-, Faslpr/lpr and OPN-/-Faslpr/lpr mice (a pool 
of 3 animals per group) were mechanically disaggregated using the bottom of a syringe. 
Then, cell suspensions were divided in two samples, to be separately stained in order to 
obtain lymphoid and myeloid populations. Flow cytometry panel for lymphoid cells 
comprised the following antibodies:  
Marker Fluorochrome Company Clone Catalogue n° 
CD19 FITC BD CL1D3 557398 
CD3  PE TONBO 145-2c11 50-0031-u500 
CD8 PerCP-Cy5.5 TONBO 53-6.7 65-0081-U100 
CD4 APC TONBO RM4-5 20-0042-U100 
B220 APC-Cy7 BD RA3-6B2 552094 
 
On the other hand, to separate myeloid cells, splenocytes were labeled with:  
Marker Fluorochrome Company Clone Catalogue n° 
F480  FITC TONBO BM8.1 35-4801-U500 
CD169 PE eBioscience SER-4 12-5755-82 
CD11c PerCP-Cy5.5 BD HL3 560584 
GR-1 PE-Cy7 eBioscience RB6-8C5 25-5931-81 
CD11b APC eBioscience M1/70 17-0112-83 
B220  APC-Cy7 BD RA3-6B2 552094 
 
Sorted cells were collected in 10% FBS RPMI supplemented with β-mercaptoethanol 
and 2 mM EDTA, washed in PBS and then dry pellets were stored at -80°C. From dry 
pellets RNA was extracted and RT-PCR was performed.  
 
3.14 Vector construction and lentiviral particles production 
 
Lentiviral vectors containing the sequences encoding either for the full-length (Spp1-




obtained by cloning the Spp1 full-length sequence (from pUC57-Spp1 plasmid, from 
DBA Italia) or the iOPN sequence (kind gift from ML. Shinohara, Durham, North 
Carolina) into the lentiviral backbone pLVX-IRES-ZsGreen1. The empty pLVX-IRES-
ZsGreen1 was used as control. 
The production of lentiviral particles was performed using a third-generation packaging 
system involving the transfection of 293T producer cells. In particular, 5x106 cells were 
seeded in 150mm plates using 10% FBS Iscove’s IMDM (Lonza, #12-722F) and, the 
day after, a co-transfection was carried out using CaCl2 of four plasmids: 16,25 µg of 
pMDLg/pRRE, 6,25 µg of pRSV-REV, 8,75 µg of envelope plasmid (pMD2-VSV-G) 
and 25 µg of the lentiviral vector with the gene of interest. After 24 h, the supernatant 
was removed and fresh medium was added. The next day supernatants containing viral 
particles were collected, centrifuged at 1500 rpm for 5 min to exclude residual cells and 
passed through a 0.45 mm filter.  
 
3.15 Overexpression of sOPN and iOPN in DLBCL cell lines  
 
2x105 cells were resuspended in the viral supernatants and seeded in 6-well plates. After 
24 h the medium was changed and, two days later, the percentage of infected cells was 
assessed by flow cytometry evaluating the percentage of GFP+ cells. GFP+ cells were 
sorted to obtain a pure population of GFP-expressing cells. To confirm the expression 
of OPN at transcript level, 1x106 cells were seeded in 6-well plates and RNA was 
extracted the day after, while to check the protein level of either sOPN or iOPN, 
1,5x106 cells were seeded in 6-well plates with or without the inhibitor of protein 
secretion BFA (Brefeldin A from Penicillium brefaldianum, Sigma, #B7651-5MG) at 
the concentration of 5µg/ml for 3 hours. Cells were collected for western blot analysis. 
 
3.16 Immunofluorescence on cytospin preparations 
 
To perform immunofluorescence on cytospin preparations 6x104 cells were deposited 
on glass slides through centrifugation. The day after, cells were fixed with 
paraformaldehyde 4% in PBS for 10 minutes and, after a fast wash in PBS, 





For OPN staining, after a washing step, cells were blocked with BSA (Sigma, #A7906-
100G) 2% in PBS for 30 minutes, and incubated with antibody a-OPN (rabbit anti-
mouse osteopontin, clone EPR21138, #218237) for 2 hours. Then, cells were washed 
and incubated with Alexa-Fluor 555 conjugated donkey anti-rabbit IgG (H+L) 
polyclonal antibody (Invitrogen; #A-31572) for 30 minutes.  
For OPN/CD63 double staining, cells were blocked with BSA (Sigma, #A7906-100G) 
2% in PBS added with a-CD16/32 1:100 (Thermofisher, #14-0161-86) antibody for 30 
minutes. Then, cells were incubated with antibody a-OPN (rabbit anti-mouse 
osteopontin, clone EPR21138, Abcam, #218237) and a-CD63 (polyclonal goat anti-
mouse, SICGEN, AB0047-200) for 2 hours. Then, cells were washed and incubated 
with Alexa-Fluor 555 donkey anti-rabbit IgG (H+L) antibody (Invitrogen; #A-31572) + 
Alexafluor 633 donkey anti-goat IgG (H+L) antibody (Invitrogen, #A21082) for 30 
minutes.  
Nuclei were highlighted with DAPI (Thermofisher, #D1306) for the last 10 minutes. 
Cover glasses were mounted using ProLong Gold antifade reagent (Invitrogen, 
#P36934). The day after, fluorescent images were acquired with Leica DM4 B optical 
microscope equipped with a DFC450 digital camera.  
 
3.17 Cell viability assay 
 
4x103 cells were seeded in 96-well plates. Cell proliferation Kit XTT (PanReac 
Applichem, #A8088) was used to evaluate the proliferation of DLBCL cells at 24, 48 
and 72h. The optical density was evaluated by Spark Multimode microplate reader. 
 
3.18 Injection of parental and transduced OPL239 lymphoma cells in 
BALB/c and OPN-/- mice 
 
BALB/c and OPN-/- mice were sublethally irradiated using “RS 2000 RAD Source 
Technologies” instrument, with a dose of 5 Gy. 4 hours after irradiation, 5x105 cells (for 
parental cell lines) or 1x105 cells (for Spp1-IRES Green, iOPN-IRES Green and IRES 
Green variants) were resuspended in 200 µl of 0.9% NaCl with a 1 ml syringe and 
intravenously injected into the tail vein. About 10 days after the injection, at first signs 
of distress, mice were sacrificed and swelled organs (spleen and liver) were collected 





3.19 GEP on human lymphomas 
 
Raw CEL files data were downloaded through package GEOquery from public dataset 
GSE4475, containing gene expression profile from 221 DLBCL patient (58 ABC, 120 
GC-DLBCL, 43 unclassified). Then, raw data were imported in R software through 
function readAffy from affy package and normalized with the RMA function. Quality 
control was performed, and than probe annotation was made with hgu133a annotation. 
Probes that did not match any gene symbol were removed. Multiple probes that were 
linked to the same gene symbol were collapsed through function collapseRow with 
method maxRowVariance from WGCNA package. 
Differentially expressed genes between ABC and GCB patients were calculated through 
limma linear models and p.value was corrected with the Benjamini and Hockberg 
method.  
 
3.20 Statistical analysis 
 
Value differences between two groups were assessed by student t test. Differences 
among more than two groups was evaluated through ordinary one way ANOVA. When 
values were associated with two categorical variables, two way ANOVA was used to 
assess differences among two or more groups. Differences were considered statistically 






4.1 Autoimmunity severity of Faslpr/lpr mice in absence of osteopontin 
 
To assess whether in autoimmune-prone Faslpr/lpr mice serum levels of OPN increase 
along disease progression, as already described for patients and mice affected by some 
inflammatory disorders [121,122], we evaluated OPN in mouse serum at different time 
points by ELISA. In line with the literature, we found that OPN is released along 
autoimmunity progression, from 2 months, when mice started showing initial signs of 
autoimmune disease, to 6 months, time of sacrifice, with a peak at 5 months of age (Fig. 
10).  
                                      
Figure 10. OPN secretion in the serum of autoimmune mice. ELISA measurement of OPN in sera 
from Faslpr/lpr mice at 2, 5 and 6 months of age. OPN was already secreted at early stages, its level 
significantly increased at 5 months and decreased at late stages (*, P<0.05; Ordinary one way ANOVA). 
Sera from BALB/c and OPN-/- mice were tested as controls. Data are expressed as ng/ml and are a pool 
of 2 different experiments.           
To investigate whether OPN deficiency affected the SLE-like syndrome of Faslpr/lpr 
mice at different stages of the disease, we recorded lymph node swelling along time, 
from first appearance (around 2 months) until sacrifice (around 6 months). Despite a 
positive association between OPN and several autoimmune disorders, including SLE, 
has long been described [120], we found that Faslpr/lpr and OPN-/-Faslpr/lpr did not show 
any significant difference in the number (Fig. 11A, left) and volume (Fig. 11B, right) of 




displayed great variability in lymph node volume.  
                   
 
Figure 11. Lymph node swelling in autoimmune mice. Curves related to neck, axillary and inguinal 
lymph node swelling of autoimmune mice showing that both the number (A) and the mean volume (B) 
were similar between Faslpr/lpr and OPN-/-Faslpr/lpr mice. 
 
Accordingly, the evaluation of auto-antibodies against self-antigens, which are a typical 
feature of autoimmune diseases [2, 51], confirmed a similar level of autoimmunity in 
the two strains. Indeed, the level of auto-antibodies against double strand (ds) and single 
strand (ss) DNA (Figure 12A and 3B) assessed by ELISA on mouse sera collected at 
different time points (2, 5 and 6 months) showed the expected increase along disease 
progression but no significant difference between Faslpr/lpr and OPN-/-Faslpr/lpr mice.     
    
Figure 12. Auto-antibodies production in autoimmune mice. ELISA measurement of IgG anti-dsDNA 




anti-dsDNA significantly increased during time (*, P<0.05, **, P<0.01; Two-way ANOVA), but no 
differences were found between the two strains. Data are expressed as U/mL.  
 
The Faslpr/lpr mutation leads to an expansion in the secondary lymphoid organs (SLOs) 
of the so-called “double negative” auto-reactive T cells (as they do not express neither 
CD4 nor CD8 while are positive for CD3 and B220) deriving from precursors unable to 
die through apoptosis in the thymus [140]. Thus, we also evaluated through flow 
cytometry the percentage of this population in the spleen of autoimmune mice at time of 
sacrifice, as another parameter of the autoimmune severity. Interestingly, despite no 
significant difference in lymph node swelling and auto-antibody serum levels, we found 
a higher expansion of CD3+B220+ cells in Faslpr/lpr than OPN-/-Faslpr/lpr mice (Fig. 13A, 
left). Notably, we found expansion of double negative cells also in the peripheral blood 
that mirrored the finding in the spleen, with increased number of CD3+B220+ cells in 
OPN-competent mice compared to OPN-deficient ones (Fig. 13B, right). In agreement 
with the data on double-negative cell expansion, the histopathological evaluation of 
mouse spleens revealed a marked expansion of the white pulp due to the massive 
infiltration of autoreactive lymphocytes in Faslpr/lpr mice, that was less evident in OPN-




     
Figure 13. Expansion of autoreactive T cells in autoimmune mice. A) Flow cytometry analysis 
showing that the relative number of splenic autoimmune CD3+B220+ T cells was significantly lower in 
OPN-/-Faslpr/lpr than Faslpr/lpr mice at about 5-6 months of age (***, P<0.001; Student t test). The graph 
shows a pool of different experiments. B) Flow cytometry analysis showing that CD3+B220+ T cells 
significantly decreased in the peripheral blood of 5-month-old OPN-deficient autoimmune mice 
compared with age-matched OPN-competent ones (*, P<0.05; Student t test). The graph refers to one 
representative experiment. C) Histopathological analysis of spleen samples from Faslpr/lpr and OPN-/-
Faslpr/lpr mice showing a marked expansion of the white pulp by reactive lymphoid cells (black arrows) in 
5-month-old OPN-competent animals, less marked in aged-matched mice lacking OPN. OPN-/-Faslpr/lpr 
spleens, in most cases, were characterized by initial lymphomatous foci, as the illustrated example (black 
arrows). Magnification 20x (left) and 40x (right). 
Altogether these data suggest a less severe autoimmunity in the absence of OPN, 
highlighted by a reduced expansion of auto-reactive double-negative T cells, despite 
other autoimmune features, such as lymph node swelling and auto-antibody titers, do 





4.2 OPN-/-Faslpr/lpr mice develop lymphoma with higher incidence than 
Faslpr/lpr mice.  
 
In order to evaluate the impact of the absence of OPN in the autoimmunity-driven 
lymphomagenesis that characterises aged Faslpr/lpr mice [52], we compared the incidence 
of splenic lymphomas in Faslpr/lpr and OPN-/-Faslpr/lpr mice at about 5-6 months of age. 
Unexpectedly, we found a much higher incidence of lymphoma in OPN-/-Faslpr/lpr mice 
than Faslpr/lpr animals [69% and 33% of cases, respectively (Fig. 14)]. As illustrated 
above, in figure 13C, histopathological analysis of the spleens of Faslpr/lpr mice revealed 
a marked expansion of the white pulp by pleomorphic lymphoid cells with irregular 
nuclei and variable size from small to medium cells (autoreactive T cells), while the 
same analysis on OPN-/-Faslpr/lpr spleens highlighted a subversion of the parenchymal 
architecture by a monomorphic proliferation of large elements, with abundant 
cytoplasm and central nuclei, with immunoblastic morphology. The features of these 
proliferating atypical elements suggest that these tumours are high-grade diffuse large B 
cell lymphomas, with morphology resembling the activated type (ABC-DLBCL).  
                   
Figure 14. Incidence of splenic lymphoma in autoimmune mice. Graph showing that the incidence of 
splenic lymphoma is higher in OPN-/-Faslpr/lpr (n=48) than Faslpr/lpr (n=46) mice at about 5-6 months of age 
(69% and 33% and respectively). (****, P < 0.0001; Chi-square two-tailed test).  
Flow cytometry analysis of splenic B cells with the classical B cell markers, CD19, 
B220 and IgM, showed in 5/6-month old OPN-/-Faslpr/lpr mice a population of CD19+ 
cells that expressed variable levels of B220 and low to negative expression of surface 





                                
Figure 15. Flow cytometry characterization of autoimmune CD19+ B cells. Gates illustrating that 
CD19+ cells from OPN-/-Faslpr/lpr mice were characterized by a low expression of surface IgM. 
 
4.3 Lymphomas developing in OPN-/-Faslpr/lpr mice show features of the 
activated type of diffuse large B cell lymphoma (ABC-DLBCL) 
 
As the different subtypes of DLBCL, GC-DLBCL and ABC-DLBCL, classified 
according to the cell of origin, are characterized by a specific and distinct pattern of 
gene expression [64], we then verified key molecular features in B cell lymphomas 
spontaneously developing in OPN-/-Faslpr/lpr mice to confirm the histopathological 
analysis suggestive of ABC-DLBCL subtype. To this aim we selected spleen samples 
from both Faslpr/lpr and OPN-/-Faslpr/lpr mice showing an overt lymphoma development 
for a correct comparison.  
As illustrated in the immunofluorescence images of figure 16, while tumours developed 
in Faslpr/lpr mice were positive for BCL6, a marker generally expressed by human GC-
related DLBCLs, OPN-/-Faslpr/lpr lymphomas did not show any positivity for this marker. 
Notably, lymphomas arose in OPN-deficient autoimmune mice were found to express a 
higher level of c-MYC (Fig. 16), an oncogene usually amplified in the so called “double 
expressor” lymphomas, according to the double expression of c-MYC and BCL2, than 
OPN-sufficient counterparts.  These markers, together with IRF4, belong to the typical 




                    
Figure 16. Evaluation of lymphoma phenotype by IF. Immunofluorescence staining on splenic tissues 
showing that BCL6 was expressed only by Faslpr/lpr lymphomas (like human GC.DLBCLs), while OPN-
deficient tumours express c-MYC (resembling human ABC-DLBCLs). PAX5 was used as a pan-B cell 
marker. Magnification 20x. 
To further support our hypothesis of ABC-DLBCL lymphoma, we analysed these three 
markers by western blot on CD19+ B cells purified through immune-magnetic beads 
from the spleen of Faslpr/lpr and OPN-/-Faslpr/lpr mice and found them more expressed in 
samples from OPN-deficient autoimmune mice (Fig. 17A).  Interestingly, B cells 
derived from OPN-deficient animals showed also a higher activation of STAT3 
pathway (ph-STAT3), generally associated with B cell survival and proliferation (Fig. 
17A). The increased activation of ph-STAT3 was also confirmed by both 
immunohistochemical and immunofluorescence staining on spleen sections from both 
autoimmune mice (Fig. 17B).  





Figure 17. Evaluation of lymphoma phenotype by Western Blot, IHC and IF. A) Western blot on 
purified CD19+ B cells from OPN-competent and deficient autoimmune mice. CD19+ B cells lacking 
OPN showed a stronger expression of BCL2, c-MYC and IRF4, as well as ph-STAT3, compared to 
Faslpr/lpr B cells. Lymphoma cell line, OPL241 has been used as positive control. B) 
Immunohistochemistry staining (upper panels) on FFPE spleens showing the stronger expression of ph-
STAT3 in OPN-deficient lymphomas comparing with OPN-sufficient ones. (Magnification 20x). The 
immunofluorescence staining (lower panels) for PAX5 and ph-STAT3 illustrates the same up-regulations 
in OPN-/- tumours. Magnification 20x. 
 
As ABC-DLBCLs are generally the most aggressive, we also compared the proliferative 
capacity of lymphomatous B cells from Faslpr/lpr and OPN-/-Faslpr/lpr mice. As 
demonstrated by immunofluorescence for the proliferation marker ki67 on 
lymphomatous spleens (Fig. 18A) and confirmed quantitatively by flow cytometry 
analysis performed on different cohorts of mice (Fig. 18B), there was a significantly 




Figure 18. Ki67 expression in B cells from autoimmune mice. Immunofluorescence staining for PAX5 
and Ki67 on FFPE spleens showing that OPN-deficient tumours were characterized by a strong 
expression of Ki67. Magnification 20x. B) Flow cytometry analysis showing a significantly higher 
number of CD19+Ki67+ cells in the spleen from OPN-/-Faslpr/lpr than Faslpr/lpr animals (*, P<0.05; Student 
t test). The graph shows a pool of two independent experiments.  
Altogether, these data strongly indicate that the autoimmunity-driven lymphomas 
developing in mice in absence of OPN are high-grade DLBCL, likely of the activated 
and “double-expressor” type, with aggressive proliferative rate. 
 
4.4 Gene expression profile on CD19+ B cells confirmed the phenotype 
of ABC-DLBCL of OPN-/-Faslpr/lpr lymphomas  
 
Aiming at investigating whether OPN deficiency affects B cell-intrinsic dynamics either 
in naive (BALB/c and OPN-/-) and/or autoimmune mice (Faslpr/lpr and OPN-/-Faslpr/lpr), 
and which genes and pathways could drive lymphomagenesis in OPN-/-Faslpr/lpr mice at 
early stages, we performed a gene expression profile (GEP) on CD19+ B cells, purified 
by magnetic beads from the spleen of animals at 5 and 8 months of age. Among 8-
month old mice, we selected by flow cytometry and histopathological analysis only 
those with overt lymphomas for both Faslpr/lpr and OPN-/-Faslpr/lpr strains.  
Comparison between the different groups are shown in the volcano plots in figure 19 
below.  Genes were considered significant with false discovery rate (FDR) ≤ 0.05 and 
fold-change ≤ -2 or ≥ 2. The greatest differences were found, as expected, when CD19+ 
cells from autoimmune and naive mice were compared, regardless of the presence of 
OPN. In samples from lymphoma-bearing Faslpr/lpr and OPN-/-Faslpr/lpr mice at 8 months 
of age, the absence of OPN modified the expression of very few genes. Interestingly, at 




Faslpr/lpr did not. To better identify the genes that could drive lymphoma development in 
OPN-deficient autoimmune mice, we selected in the 5-month time point OPN-/-Faslpr/lpr 
mice with early sign of lymphoma and OPN-competent Faslpr/lpr animals with no 
evidence of lymphomatous cells. The number of differentially expressed genes (DEG) 
at this time point, when lymphomagenesis likely occurs, were much higher than at 8 
months of age, time with overt lymphomas. 
           
Figure 19. Gene expression profile on CD19+ cells from naïve and autoimmune mice. Volcano plots 
showing the differentially expressed genes (DEG) among the various groups of animals (B/c, OPN-/-, 
Faslpr/lpr and OPN-/-Faslpr/lpr mice at 5 and 8 months of age). Green dots represent down-modulated genes 
with a FDR ≤ 0.05 and fold-change ≤ -2 and red dots represent up-modulated genes with FDR ≤ 0.05 and 
fold-change ≥ 2. All comparisons were made using limma package.   
Notably, the ABC-DLBCL like phenotype of lymphomatous B cells from OPN-/-
Faslpr/lpr mice was also confirmed by GEP, as we found up-regulated, in comparison 
with Faslpr/lpr mice, some genes (Prdm1, Prlr, Hsp90b1) (Fig. 20) that have been found 





                              
Figure 20. Differentially expressed genes between CD19+ cells from 5-month old OPN-/-Faslpr/lpr 
and Faslpr/lpr mice. List of the top 45 significantly up-regulated genes calculated through limma models. 
Genes are listed in descending order of fold change.  
Among the most up-regulated genes in the comparison of OPN-/-Faslpr/lpr with Faslpr/lpr 
mice at 5 months, we found Prdm1 (7,3-fold increase) that encodes for BLIMP1 (B 
lymphocyte induced maturation protein-1), a transcriptional repressor, target of both 
NFkB and STAT3. 
To verify the up-regulation of Prdm1 in OPN-deficient tumours, we firstly confirmed 
its significant increase on the same RNA samples used for GEP analysis (Fig. 21A). 
Then, we evaluated its expression in CD19+ cells isolated with immunomagnetic beads 
from other animals of the four strains, at about 5 months of age, confirming a trend of 




RNA Scope technology to analyse its expression in situ, on spleen sections from 5/6-
month old Faslpr/lpr and OPN-/- Faslpr/lpr mice. As illustrated in Fig. 21C, OPN-deficient 
tumours showed a higher positivity for Prdm1 probe compared to OPN-competent ones 
and to the other groups.  
       
Figure 21. Expression of Prdm1 in B cells. A) Technical validation (RT-PCR) on the same RNA 
samples used for GEP analysis showing a significant up-regulation of Prdm1 in CD19+ cells from 
OPN-Faslpr/lpr mice compared with all other groups (*, P<0.05, Ordinary one way ANOVA). B) RT-
PCR on CD19+ cells from a different cohort of mice showing a trend in the Prdm1 increase in OPN-
deficient autoimmune mice. C) RNA-scope for Prdm1 showing its strong expression in FFPE spleens 
from tumor-bearing OPN-/- mice. Magnification 40x. 
In order to evaluate whether B cells from Faslpr/lpr and OPN-/-Faslpr/lpr mice could 
activate different signaling cascades, we performed an enrichment score analysis 
through the package pathfindR on Reactome Pathway with DEG between the two 




important for B cell development and often hyper-activated in several malignancies of 
the B cells, including DLBCL, such as NOTCH pathways [69] (Fig. 22A). Interestingly, 
when performing a longitudinal analysis comparing OPN-/-Faslpr/lpr B cells at 8 months 
and 5 months, NFkB and TNF-a signaling pathways, associated with TLR cascades and 
important for B cell survival and inflammation, were significantly up-regulated at the 
late disease stage (Fig. 22B).   
          
Figure 22. Pathway analysis. PathfindR analysis on Reactome pathway illustrating the modulated 
signaling pathways in the comparison between OPN-/-Faslpr/lpr and Faslpr/lpr B cells mice at 5 months of 
age (A), and OPN-/-Faslpr/lpr mice CD19+ B cells along the disease (8 months versus 5 months) (B) (FDR 





Overall, these data indicate that the most relevant transcriptional changes in B cells 
from OPN-deficient autoimmune mice occur at early stages of the disease, when the 
absence of OPN seems to induce Prdm1 and other genes and pathways described to be 
important for sustaining lymphoid malignancies, including DLBCL.   
 
4.5 Splenic B cells undergoing malignant transformation in OPN-/-
Faslpr/lpr mice likely belong to a mature CD19+CD93- subset, but are 
neither follicular nor marginal zone B cells. 
 
In order to investigate whether B cell development within primary and secondary 
lymphoid organs is impaired in absence of OPN, bone marrow and spleen of both naïve 
and autoimmune Faslpr/lpr and OPN-/-Faslpr/lpr mice were analysed by flow cytometry 
using Hardy’s multiparametric panel able to distinguish the different B cell populations 
[142]. The gating strategy of both bone marrow and spleen is shown in figure 23A and 






Figure 23. Hardy’s gating strategy applied to bone marrow and spleen from a BALB/c mouse. A) 
Example of gating strategy for discriminating B220+CD43- stroma-dependent (A, B, C, C’) and 
B220+CD43+ stroma-independent (D, E, F) B cell populations in the bone marrow from a BALB/c 
mouse. B) Example of gating strategy to discern the different CD93+ immature (transitional 1, 2, 3) and 
CD93- mature (follicular B, marginal zone B and CD21/35-CD23-) B cell subsets in the spleen from a 
BALB/c mouse.  
As expected, the percentages of the different B cell subsets in naïve and autoimmune 
mice were different, both in the bone marrow and in the spleen, but no major difference 
were detected between OPN-competent and -deficient animals within the naïve or the 
autoimmune group (Fig. 24 A and B). However, in the spleen, the site of transformation 
of DLBCL, we interestingly noticed that, inside the mature CD19+CD93- population, 
which comprises the classical follicular B (FOB) (CD23+) and marginal zone (MZB) 
(CD21/35+) B cells, OPN-/-Faslpr/lpr mice showed a significant reduction of FOB in 
favor of an atypical CD23-CD21/35- population that was strongly increased in OPN-
deficient autoimmune animals (Figure 24B and C).  In light of this observation, we 
speculated that this atypical CD23-CD21/35- population could represent the subset 













                      
Figure 24. Quantification of the different B cell populations in bone marrow and spleen from naïve 
and autoimmune mice. A) Graphs showing the percentage of different B cell populations in the bone 
marrow (A) and spleen (B, C) from 3 B/c, 3 OPN-/-, 3 Faslpr/lpr and 3 OPN-/-Faslpr/lpr mice, assessed by 
flow cytometry. A) In the bone marrow, only differences between naïve and autoimmune mice were 
observed, but none between OPN-competent and -deficient animals inside each group.  B) In the spleen, 
besides differences between naïve and autoimmune mice, CD23+ follicular B cells (FOB) were 
significantly reduced in OPN-/-Faslpr/lpr compared with Faslpr/lpr mice (*, P<0.05; Ordinary one way 
ANOVA), while the CD23-CD21/35- fraction augmented in the same animals (**, P<0.01; Ordinary one 
way ANOVA). C) Fraction of splenic CD23+ FOB, CD21/35+ marginal zone (MZB) cells, and CD23-
CD21/35- cells from the spleens of all groups of mice. OPN-/-Faslpr/lpr showed a reduction of FOB cells 
(***, P<0.001; Two-way ANOVA) that was associated with the expansion of an atypical CD23-
CD21/35- population. (****, P<0.0001; Two-way ANOVA). Data are referred to one representative 
experiment out of 3.  
These data suggest that B cells undergoing transformation in OPN-/-Faslpr/lpr mice are a 
mature, but atypical CD21/35-CD23- population, which does not belong to neither FOB 
nor MZB cell subsets. 
 
4.6 Expression of OPN within the splenic microenvironment of 
BALB/c and Faslpr/lpr mice 
 
In order to investigate which cells are the main producers of OPN in the SLOs of both 
naïve and autoimmune mice, we firstly evaluated the mRNA level of Spp1 in the 
different immune cell populations sorted from the spleen of 3-month-old BALB/c and 
Faslpr/lpr mice (Fig. 25A). Specifically, we analysed the following cell types: CD4+ and 
CD8+ T lymphocytes, B lymphocytes (CD19+), granulocytes (CD11b+ Gr-1hi), 




macrophages (F480+CD169+) and autoimmune T cells (CD3+B220+), the latter only in 
the case of Faslp/lpr mice. Interestingly, as shown in figure 25A, immune cells expressing 
Spp1 were different between naïve and autoimmune mice, suggesting that, in such 
inflammatory scenario, cellular and molecular dynamics in SLOs could undergo 
modifications.  Notably, whereas in BALB/c mice granulocytes were the population 
expressing the highest level of Spp1, in the spleen of Faslpr/lpr mice Spp1 was mostly 
expressed by CD4+ T and CD3+B220+ cells, and, at a lower level, also by Gr1hi cells.  
Since, the mRNA level of Spp1 does not discriminate between the soluble and the 
intracellular isoforms of OPN, we evaluated its protein expression by performing IHC 
on spleen sections from naïve and autoimmune Faslpr/lpr mice. In order to understand 
whether B cell-intrinsic dynamics were responsible for the increased B 
lymphomagenesis in OPN-deficient animals, we firstly investigated the expression of 
OPN in splenic B cell zones of autoimmune mice. Notably, IHC for OPN showed a 
moderate expression of OPN by B cells in the spleen follicles of Faslpr/lpr mice that did 
not develop DLBCL, that was greatly increased in lymphomatous B cells from mice 
with lymphoma (fig. 25B). Noteworthy, the localization of OPN showed a specific and 
particular pattern, either with a cytoplasmatic distribution or with dots surrounding the 
nuclear region, suggesting that the OPN form mainly expressed by lymphomatous cells 
is the intracellular one. Remarkably, also double immunofluorescence staining 
performed on CD19+ cells purified from Faslpr/lpr mice indicates that OPN and the 
endosomal marker CD63 showed a very similar expression pattern, suggesting that, in 
autoimmune B cells, OPN has an intracellular localization, and, more precisely, 
localises in the endosomal compartment.  











Figure 25. Expression of OPN in splenic B cells. A) RT-PCR on Spp1 performed on different immune 
cell populations sorted from B/c and Faslpr/lpr spleens (pool of 4 mice per group).  Gr1hi cells were the 
main producer of OPN in B/c mice,  while CD4+, CD3+B220+ and, at a minor extent, Gr1hi cells, 
expressed Spp1 in autoimmune animals. Values are referred as 2^-DCT. B) Expression of OPN in splenic 
B cell zones.  IHC on OPN performed on splenic FFPE tissues from B/c and autoimmune mice showing 
that OPN is expressed by lymphoid cells in the splenic follicles of Faslpr/lpr mice, and its level increases 
within the lymphomatous zones in tumour-bearing mice. The localisation of OPN is intracellular, with 
dots localising nearby the nuclear membrane. Magnification 20x (left) and 40x (right). C) Double IF for 
OPN (red) and the endosomal marker CD63 (blu), showing that OPN is localised in the endosomal 
compartment of purified CD19+ cells from Faslpr/lpr mice. B/c CD19+ cells did not show detectable signal 
for OPN. Magnification 40x.  
 
IHC for OPN performed on splenic tissues showed that, apart from B cells, the protein 
is expressed also by other cell types, specifically macrophages and dendritic cells found 
to be localised in autoimmunity-caused granulomas, and by granulocytes, enriched in 




literature, also myeloid cells were characterized by the expression of intracellular OPN, 
with a staining very similar to that one observed in B cells.  
      
Figure 26. Expression of OPN by cells of the splenic microenvironment. IHC for OPN performed on 
FFPE sections from the spleen of Faslpr/lpr mice indicates that OPN is expressed by some cells of the 
microenvironment, namely macrophages, DCs and granulocytes of the perivascular zone of the red pulp. 
Magnification 40x and 20x. 
 
4.7 The activation of TLR9-MYD88 signaling pathway is enhanced in 
B cells from OPN-/-Faslpr/lpr mice 
 
To identify OPN-related pathways that could be implicated in driving B cell 
proliferation and transformation in autoimmune mice, we focused our attention on 
TLR9-MYD88 signaling pathway, since TLR9 binds double strand DNA, chronically 
circulating in the blood of autoimmune mice, and MYD88 has been described to co-
localise with, and to be regulated by, iOPN [101,108,109]. Additionally, MYD88 gene 
mutation has been identified as one of the most prevalent driver mutations in the ABC-
DLBCL [84]. 
With the purpose of investigating whether MYD88 activity is influenced by the absence 
of OPN, we isolated through immunomagnetic beads CD19+ cells from the spleen of 4-
month-old OPN-competent and -deficient animals, and stimulated them with CpG 1826, 




difference upon stimulation (Fig. 27A), flow cytometry analysis indicated that CD19+ 
B cells from OPN-/-Faslpr/lpr mice are more activated, based on the increased expression 
of CD86, compared to OPN-competent autoimmune B cells, after TLR9 triggering (Fig. 
27B). 
In agreement with the hypothesis of a more activated phenotype upon TLR9 
stimulation, the protein level of molecules belonging to MYD88 signaling, such as 
IRAK1, and IRAK4, and MYD88 itself, are up-regulated in B cells deficient for OPN, 
both in steady state conditions and after stimulation with CpG 1826 (Fig. 27C), 
suggesting that the presence of OPN is able to restrain MYD88 signaling pathway. 
Furthermore, OPN-sufficient and -deficient autoimmune CD19+ cells did not show any 
difference in the MYD88-related protein machinery when stimulated with TLR4 
(MYD88-dependent) and TLR3 (MYD88-independent) agonists LPS and Poly I:C, 
respectively (Fig. 27C). These results suggest that the negative role exerted by B-cell 
intrinsic OPN mostly involves the TLR9 cascade, at least in this specific setting.  
                 
Figure 27. Evaluation of MYD88 signaling pathway in B cells from autoimmune mice. Flow 
cytometry analysis showing that, while no differences were found between OPN-deficient and -competent 
naïve mice (A), OPN-/-Faslpr/lpr B cells had a significant increased activation, based on the expression of 
CD86, compared to Faslpr/lpr CD19+ cells (B) after 3-day stimulation with CpG 1826. (***, P<0.001, 
Two-way ANOVA). C) Representative western blot performed on CD19+ B cells purified from OPN-
competent and -deficient autoimmune mice revealing that the level of IRAK1, IRAK4 and MYD88 are 




The same increase was not found between groups after TLR4- and TLR3- triggering with LPS and Poly 
I:C, respectively. 
 
At this point, we wondered if the MYD88-dependent cascade was more activated in 
absence of OPN because of an increased amount of TLR9. For this reason, we evaluated 
its expression on CD19+ B cells through flow cytometry, finding a striking up-
regulation of the receptor in 5/6-month-old OPN-/-Faslpr/lpr mice in comparison with 
age-matched OPN-competent animals, both in terms of percentage of TLR9+ cells (Fig. 
28A) and mean fluorescence intensity (MFI) of the protein (Fig. 28B). 
            
Figure 28. TLR9 expression in B cells from naïve and autoimmune mice. Flow cytometry analysis 
showing the expression of TLR9 gated on splenic CD19+ cells from B/c, OPN-/-, Faslpr/lpr and OPN-/-
Faslpr/lpr mice. OPN-/-Faslpr/lpr mice showed a significantly higher level of CD19+TLR9+ cells (**, P<0.01; 
Ordinary one way ANOVA) and TLR9 protein level (MFI) on CD19+ cells (*, P<0.05; Ordinary one way 
ANOVA) comparing to Faslpr/lpr mice. Data in the graphs are referred to a pool of two independent 
experiments.   
 
Together, these findings indicate that the TLR9-MYD88 signaling is enhanced in B 
cells from OPN-/-Faslpr/lpr mice. To such increase, it may contribute not only a 
regulatory role exerted directly by iOPN, located in the endosomal compartment where 
TLR9 resides and signals, but also the higher expression of TLR9 in OPN-deficient B 
cells from autoimmune animals.  
 
4.8 Lymphoma cell lines established from OPN-/-Faslpr/lpr mice 
maintain the features of ABC-DLBCL 
 
In order to more easily study the molecular mechanisms behind the observed phenotype, 




Faslpr/lpr or OPN-/-Faslpr/lpr mice. To this aim, once we had indication by flow cytometry 
of a lymphomatous phenotype (CD19+B220low/+IgM-), we seeded in in vitro culture 
splenic cells (as bulk or purified CD19+ cells). After several attempts, we managed to 
obtain only two cell lines, named OPL239 and OPL241, from the spleen of two 6-
month-old OPN-/-Faslpr/lpr mice. According to histopathological evaluation and 
immunofluorescence staining of their spleen (showed in Fig. 29), while OPL239 was 
derived from an early-stage DLBCL that still preserved the nodular architecture, 
OPL241 originated from a more advanced DLBCL, already spread in the spleen.  
          
Figure 29. Phenotype of OPL239 and OPL241 cell lines through E/E and IF. Hematoxylin/eosin and 
immunofluorescence staining for PAX5/BCL6 performed on OPN-/-Faslpr/lpr mouse spleens  #239 and 
#241, from which OPL239 and OPL241 cell lines derive. According to the morphology and to PAX5 
pattern, the former lymphomas is an early stage DLBCL still preserving a nodular architecture, while the 





Both cell lines maintained in vitro the phenotype observed in the spontaneous 
lymphomas developing in vivo, with complete loss of surface IgM and positivity for 
B220 (Fig. 30). B cell lymphomas are usually B cell receptor (BCR)-dependent, 
although lymphomatous B cells that survive without BCR do exist [143]. In light of this 
evidence and of our finding of negativity for surface IgM, we wondered whether these 
lymphoma cell lines express on their membrane other surface immunoglobulins. By 
flow cytometry analysis, we observed that both cell lines maintained the expression of 
IgA, but not of IgD (Fig. 30), suggesting that they may still preserve the signaling of 
BCR.                          
                                               
Figure 30.  Flow cytometry characterization of OPL239 and OPL241 cell lines. Gates show that both 
cell lines express B220, are negative for surface IgM and IgD but are positive for IgA.  
 
Furthermore, in line with the data observed in the spontaneous lymphomas, RT-qPCR 
showed that both cell lines expressed low levels of Bcl6 and high levels of Irf4/Mum1, 




confirmed by western blot (Fig. 31B).  
We also compared the two cell lines for the activation of STAT3 and NFkB signaling 
pathways through Western blot. OPL241 line showed a stronger expression of phospho- 
and total p65, ph-STAT3 and of BCL2, in agreement with the histological evaluation of 
the original lymphomas (Fig. 31B) 
 
Figure 31. Phenotype of OPL239 and OPL241 cell lines through RT-PCR and Western Blot. A. RT-
PCR showing that OPL239 and OPL241 cell lines did not express Bcl6, while were positive for Bcl2, Irf4 
and c-myc. CD19+ from B/c and OPN-/-mice were used as controls. Values related to transcripts are 
referred as 2^-DCT.  B) Western blot on OPL239 and OPL241 lysates illustrating the protein level of 
BCL2, c-MYC, IRF4 and the basal level/activation of STAT3 and NFkB (p65) pathways. OPL241 was 
characterized by a greater expression of BCL2, ph-STAT3 and ph/total-P65 compared with OPL239.  
 
Additionally, both OPN-deficient cell lines express also CXCR4 (Fig. 32) another 




                                   
Figure 32. Expression of CXCR4 by OPL239 and OPL241 cell lines. Flow cytometry analysis 
showing that OPL239 and OPL241 cell lines expressed high level of CXCR4 (like human ABC-
DLBCLs).                   
In line with the finding that the B cell population expanding and likely transforming in 
OPN-/-Faslpr/lpr mice is the mature CD23-CD21/35- one, we evaluated the expression of 
these markers in OPL239 and OPL241 lines. Indeed, we found that, besides being 
negative for CD93, they were negative for CD21/35 and expressed very low level of 
CD23 (Fig. 33). 
                           
Figure 33. Hardy’s multiparametric panel applied to OPL239 and OPL241 cells. Flow cytometry-
derived gates showing that OPL239 and OPL241 DLBCL cell lines were negative for CD93 and 





4.9 In vivo injection of DLBCL cell lines in OPN-/- hosts increases 
their ABC-like features. 
 
To assess the in vivo tumorigenicity of the two lymphoma cell lines, we firstly 
intravenously injected them into immune-compromised mice (nu/nu nude mice and sub-
lethally irradiated (5Gy) BALB/c mice), or immunocompetent (non-irradiated BALB/c 
mice), in the latter case at different doses (from 2,5x105 up to 1x106 cells). We found 
that both OPL239 and OPL241, identified as CD19+B220+/-IgM- cells, were able to 
grow in spleen and liver only in nude (Fig. 25A) and irradiated mice (Fig. 34B) but not 
in immunocompetent animals. 
 




       
Figure 34. Injection of OPL239 and OPL241 in nude and irradiated B/c mice. Flow cytometry-
derived plots showing the phenotype (CD19+IgM-B220+/-) of OPL239 and OPL241 grown in spleen 
(top) and liver (bottom) of nude (A) and sub-lethally-irradiated B/c mice (B). Spleens from nude and 
irradiated B/c mice were used as controls.  
 
Additionally, in order to evaluate a possible role of the splenic microenvironment, either 
OPN-competent or -deficient, in their aggressiveness and phenotype, we injected 
OPL239 and OPL241 lines in sub-lethally irradiated BALB/c and OPN-/-hosts to study 
eventual difference in tumor growth and gene expression.  
Considering that lymphomatous B cells have invaded the whole spleen of the animals 
from both strains (Fig. 35A), and comprised the totality of B cells present in the organ, 
we could not detect any difference in tumor take. However, we have been able to isolate 
tumor cells and analyse their expression of relevant genes by RT-PCR. Interestingly, 




target gene Prdm1 when grown in OPN-/- animals, in comparison with lymphomas 
derived from OPN-competent mice (Fig 35B and C). In addition, we also observed a 
trend in the increase of the NF-kB target gene Il6 and of the ABC/DE-DLBCL markers 
Bcl2, Irf4 and c-myc in tumors from both cell lines when isolated from OPN-deficient 
hosts (Fig. 35B and C).  
 
                






                           
Figure 35. Injection of OPL239 and OPL241 in B/c and OPN-/- hosts. A) Flow cytometry analysis of 
the spleen of 4 B/c and 4 OPN-/- mice intravenously injected with OPL239 (left) and OPL241 (right), 
showing that tumour cells infiltrated the whole organ. One B/c and one irradiated B/c were used as 
controls. RT-PCR performed on OPL239 (B) and OPL241 (C) cells re-isolated from the spleen of 4 B/c 
and 4 OPN-/- after 10 days from i.v. injection. Prdm1 was significantly upregulated in OPL239 (**, 
P<0.01; Student t test) and OPL241 (*, P<0.05, Student t test) if re-isolated from OPN-/- hosts. Bcl2, Irf4, 
c-myc and Il6 showed no differences or a trend of increase in the same conditions. CD19+ cells from B/c, 
OPN-/- and the cell lines cultured in vitro were used as controls. 
 
These findings may suggest that an OPN-deficient stroma is more supportive than a 
competent one in sustaining the dynamics of B lymphomagenesis, in agreement with 
the results observed in the spontaneous mouse model (see paragraphs 13). 
 
4.10 Intracellular OPN prevents CpG-mediated STAT3 and/or NFkB 
activation in OPL239 and OPL241 
 
Aimed at understanding which isoform of OPN is relevant in protecting from 
autoimmunity-driven lymphomagenesis, we decided to overexpress in the two 
lymphoma cell lines, which were derived from OPN-deficient autoimmune mice, either 




lentiviral vectors expressing, beside OPN sequence, also the GFP sequence as reporter. 
We infected cells with vectors expressing only IRES Green (empty/control vector), 
Spp1-IRES Green and iOPN-IRES Green, and, after sorting them based on GFP 
positivity, we checked the transcript level of Spp1 through RT-PCR (Fig. 36A) and 
protein level of OPN, with or without the presence of Brefeldin A (BFA) to block 
protein secretion, through Western blot (Fig. 36B). Of note, the over-expression of the 
full-length secreted form was lower compared to that of the intracellular OPN, in both 
cell lines.  
                     
Figure 36. Overespression of sOPN and iOPN in OPL239 and OPL241.  RT-PCR (A) and Western 
blot (B) on parental and IRES-Green based cells illustrating the Spp1 mRNA level and OPN protein 
expression (in presence or not of BFA, that blocks protein secretion), respectively. Both techniques 
indicated that both Spp1- and iOPN overexpressing lines expressed OPN, although the infection was less 
efficient in the former type of cells. 4T1 mammary cell line was used as positive control. 
 
Additionally, in order to visualize the localization of the ectopic OPN in the 




preparations (Fig. 37). We found that Spp1-overexpressing OPL241 cells are 
characterized by a small amount of OPN in steady state conditions, as it is secreted, 
while in presence of BFA the protein level increases and shows a cytoplasmatic/Golgi 
distribution, as expected. Interestingly, intracellular OPN, whose expression does not 
change upon BFA treatment, shows a peri-nuclear distribution.  
 
 Figure 37. Representative IF for OPN on OPL241 parental and IRES Green-based variants. Spp1-
overexpressing cells showed a discrete amount of OPN, increased upon BFA treatment, that preserved a 
cytoplasmatic/Golgi distribution. In iOPN-overexpressing cells, OPN showed a peri-nuclear distribution 
and did not increase upon BFA treatment. Magnification 40x.  
 
To mimic the physiological scenario present in autoimmune mice in which ds-DNA 
constantly circulates in the blood and to trigger TLR9, we decided to stimulate parental 
and genetically-modified cells with the TLR9 agonist CpG 1826 and check the 
activation of pathways important for B cell survival and proliferation. Firstly, as shown 
in figure 38A, we confirmed the expression of TLR9 through flow cytometry in both 
parental cell lines.  Remarkably, as concerns OPL239 variants (Fig. 38B), we found that 
the activation of STAT3 (ph-STAT3) is almost abolished in iOPN-overexpressing cells, 
despite similar amount of total protein, suggesting that the presence of iOPN is able to 
inhibit TLR9-MYD88-STAT3, whereas secreted OPN does not affect this pathways. 
Differently, NFkB pathway does not seem significantly modulated by 30-minute CpG 
stimulation in all cell variants, although the overall level of both total and phospho-p65 




stimulation may not be the right time point to detect NF-kB activation in this specific 
setting. 
In the same experiment we also collected RNA at 3h and 6h after CpG stimulation, to 
check the induction of genes target of the TLR9 cascade, such as Il6 and Tnfa (Fig. 
38C). Interestingly, at 3h time point we found that OPL239 over-expressing Spp1 
significantly up-regulated both genes upon TRL9-triggering, whereas in the presence of 
iOPN, the level of the same transcripts did not change after administration, in line with 
Western Blot result. At 6h, all genes returned at their basal level as non-stimulated cells, 
suggesting a fast kinetics of CpG stimulation in OPL239 cell line variants. 
 




          
 
Figure 38. Evaluation of TLR9-MYD88 pathway in OPL239 cell lines. A) Flow cytometry plots and 
histograms showing that OPL239 and OPL241 cell lines express TLR9. B) Western blot analysis 
performed on OPL239 parental cells and IRES Green-based variants, stimulated or not with TLR9 
agonist CpG 1826 for 30 min. Only in OPL239 iOPN-IRES Green the CpG-mediated activation of 
STAT3 is dampened. iOPN-expressing cells showed a minor level of ph- and total p65 regardless the 
stimulus. C) Evaluation through RT-PCR of Il6 and Tnfa in OPL239 parental and IRES-Green-based 
cells, after 3h- and 6h-stimulation with CpG 1826. Comparing all variants in the condition of 3h-
stimulation, OPL239 Spp1-IRES Green showed a significantly higher level of Il6 compared with parental 
cells (***, P<0.001; Two-way ANOVA), cells with the empty vector (****, P<0.0001; Two-way 
ANOVA) and iOPN-overexpressing cells (****, P<0.0001; Two-way ANOVA). In the setting of 3h-
stimulation, OPL239 Spp1-IRES Green showed a significantly increased level of Tnfa compared with 
iOPN-overexpressing cells (*, P<0.05; Two-way ANOVA) and cells with the empty vector (**, P<0.01; 
Two-way ANOVA), but decreased compared to parental cells (***, P<0.001, Two-way ANOVA). 
 
The same experiment was performed with OPL241 and its variants, finding, 
unexpectedly, a different behavior. Basically, OPL241 and its variants seem less 
sensitive to TLR9 stimulation than OPL239, as none of them show significant 
activation of both STAT3 and p65 pathways, with only a slight induction of ph-STAT3 
in the parental OPL241 line (Fig. 39A).  The most relevant observation was the 
complete absence of total and, consequently, of phospho-p65 in OPL241 iOPN-IRES 




pathway also at transcriptional level. Furthermore, the phosphorylation of STAT3 was 
reduced in iOPN-overexpressing cells regardless the stimulus (Fig. 39A).   
OPL241 cell variants showed differences also in the transcriptional level of Il6 and Tnfa 
in comparison to OPL239 cells. Particularly, Il6 was up-regulated at 3h time point in 
OPL241 over-expressing Spp1 at the same level of control cells, while iOPN-
overexpressing cells did not show any increased expression (Fig. 39B). Only the 
parental OPL241 line up-regulated Tnfα expression upon TLR9 triggering, whereas its 
levels were not modified in any of the genetically-modified variants (Figure 39B). 
         
                          




Figure 39. Evaluation of TLR9-MYD88 pathway in OPL241 cell lines. A) Western blot analysis 
performed on OPL241 parental and IRES-Green-based cells, stimulated or not with TLR9 agonist CpG 
1826 for 30 min. OPL241 iOPN-IRES Green totally abrogated the expression of both ph-NFkB and total 
NFkB, while no effect on STAT3 could be detected upon stimulus. B) RT-PCR on Il6 and Tnfa after 3 
and 6 hours of CpG 1826 stimulation. Il6 was significantly decreased after 3h-stimulation in OPL241 
iOPN-IRES Green comparing with parental cells (**, P<0.01, Two-way ANOVA), OPL241 IRES Green 
(**, P<0.01, Two-way ANOVA), and OPL241 Spp1-IRES Green (***, P<0.001, Two-way ANOVA). At 
the same time point, OPL241 showed a significant higher level of Tnfa compared with cells with the 
empty vector (**, P<0.01; Two-way ANOVA), Spp1- (***, P<0.001; Two-way ANOVA) and iOPN-
overexpressing cells (***, P<0.001; Two-way ANOVA).  
 
A possible explanation for the different behaviour of the two cell lines upon genetic 
modification with OPN-expressing vectors could be a baseline different activation of 
the MYD88 pathway in OPL241 in comparison to OPL239, as STAT3 and p65 
pathways were more activated even at steady state conditions in OPL241 cells, as 
already described in Figure 40B. This hypothesis is in line with the histological 
evaluation of the spleens from which OPL239 and OPL241 have been derived, as 
OPL239 is an early-stage lymphoma, likely more dependent on the microenvironment 
than OPL241, which derives from a more advanced and aggressive DLBCL. 
These results overall indicate that the intracellular isoform of OPN could represent a 
brake in MYD88-triggered STAT3 and NFkB pathways in autoimmunity-driven B cell 
lymphomas, likely explaining why in OPN-deficient mice the transformation of B cells 
occurs more frequently, and likely faster, than in OPN-competent animals. 
 
4.11 In vivo effect of OPN over-expression in lymphoma cells 
 
At this point, we wondered whether the over-expression of either sOPN or iOPN in 
lymphoma cells could affect their behaviour in vivo, in terms of tumor growth and 
immune infiltrate. We therefore intravenously injected OPL239 IRES Green, Spp1-
IRES Green and iOPN-IRES Green cells in sub-lethally irradiated BALB/c mice.  
Notably, as shown in figure 40A, OPL239 Spp1-IRES Green cells showed a striking 
increase in tumor take, assessed as CD19+GFP+ population, both in spleen and liver, in 
comparison to control and iOPN-overexpressing cells, confirming the well-established 
pro-tumorigenic role of secreted OPN also in this hematological setting. Remarkably, 
iOPN-IRES Green cells showed a reduced tumor take compared with OPL239 IRES 




levels than spleen, Spp1 over-expression in tumor cells confirmed the increased growth, 
whereas the tumor take of control cells was too low to detect any difference with iOPN-
expressing cells.  
These results indicate that iOPN not only does not exert the pro-tumorigenic and pro-
inflammatory activities as sOPN does, but also that it may be able to restrain DLBCL 
growth.  
In line with these findings, we found that OPL239 Spp1-IRES Green tumors promoted a 
significant enrichment in CD4+Foxp3+ T regulatory (Tregs) cells in the spleen, 
compared with OPL239 IRES Green and OPL239 iOPN-IRES Green cells, that were 
also highly proliferating, based on Ki67 expression (Fig. 40B). As concerns the myeloid 
compartment (C), OPL239 Spp1-IRES Green showed a marked reduction of the total 
CD11b+ cells compared with OPL239 IRES Green and OPL239 iOPN-IRES Green 
cells, presumably due to the significantly diminished percentage of F480+ cells 





                        
 
   
          
Figure 40. Injection of OPL239 variants in BALB/c mice. A) Flow cytometry analysis showing that, in 
the spleen, OPL239 overexpressing Spp1 had a significantly higher tumour expansion than OPL239 IRES 
Green (****; P<0.0001; Ordinary One-way ANOVA) and OPL239 iOPN-IRES Green (****, P<0.0001; 
Ordinary one way ANOVA). iOPN-overexpressing cells showed a significant lower tumor growth 
compared with the control cells (*, P<0.05; Ordinary one way ANOVA). In the liver, Spp1-




(****, P<0.0001; Ordinary one way ANOVA) and cells overexpressing iOPN (****, P<0.0001; Ordinary 
one way ANOVA). B) Flow cytometry analysis showing that Spp1-overexpressing cells recruited a 
significantly higher number of Treg cells compared with OPL239 IRES Green (****, P<0.0001; Ordinary 
one way ANOVA) and iOPN-IRES Green (****, P<0.0001; Ordinary one way ANOVA).  Treg cells 
were also more proliferating (Ki67+) in the same comparisons (****, P<0001; Ordinary one way 
ANOVA). C) Flow cytometry-derived graphs illustrating that Spp1 overexpressing cells showed a 
significantly reduced percentage of CD11b+ cells compared with empty vector (**, P<0.001; Ordinary 
one way ANOVA), and a trend of reduction compared to iOPN overexpressing line. OPL239 Spp1-IRES 
Green significantly reduced F480+ macrophages in comparison to the other two variants. (**, P<0.01; 
Ordinary one way ANOVA). An irradiated B/c mouse was used as control. 
 
To assess whether the different in vivo growth was due to a different proliferation rate 
in vitro, we analysed their proliferation by XTT assay (Fig. 41), finding no significant 
difference between the different variants.  
                                                     
Figure 41. Proliferation capacity of OPL239 variants in vitro. XTT-related graph illustrating the 
proliferation capacity of OPL239 variants along time (0 h, 24 h, 48 h, 72 h). No significant differences 
were found among cell lines. The graph shows a pool of two independent experiments.  
 
Altogether, these results confirm that the over-expression of secreted OPN by 
lymphoma cells induces an aggressive phenotype, associated to a tolerant 
microenvironment, allowing tumour cells to proliferate and colonize organs and 
indicate that, on the contrary, iOPN does not exert such effects but rather, it may 
restrain inflammation and possibly tumor growth. 
 
4.12 OPN-/-Faslpr/lpr mice show alterations in the splenic immune 
populations during the lymphomagenesis process 
 
Although DLBCL seems to be one of the lymphoma subtypes less dependent on the 
tumor microenvironment [144], we wanted to assess whether the absence of OPN 
affected other immune cells of the SLO microenvironment in association with either 




performed a flow cytometry analysis on the spleen of 5/6-month-old mice to evaluate 
the percentage of B cells (CD19+), autoimmune cells (CD3+B220+), CD4+ and CD8+ 
T cells, myeloid cells (CD11b+), and, among the latter, granulocytes (Gr1hi), monocytes 
(Ly6chi), classical dendritic cells (cDCs ;CD11c+B220-) and plasmacytoid dendritic 
cells (pDCs; CD11c+B220+). As illustrated in figure 42, an expected massive 
infiltration of CD3+B220+ autoreactive T cells was observed in Faslpr/lpr mice, higher 
than that in OPN-deficient autoimmune animals. Notably, Faslpr/lpr mice showed also a 
higher percentage of pDC (CD11c+B220+ cells), in line with the exacerbate 
autoimmunity of this strain and with the role of this population in autoimmunity. 
CD19+ cells showed a reduction in their relative number in OPN-deficient autoimmune 
mice compared with OPN-competent ones, but were characterized by a higher 
proliferation rate (CD19+Ki67), as already described in figure 18. No differences in the 
other lymphoid populations were observed among OPN-competent and -deficient 
strains. 
A significant difference between Faslpr/lpr and OPN-/-Faslpr/lpr animals was observed in 
the myeloid compartment (CD11b+) that was expanded in the latter strain, mainly due 







Figure 42. Flow cytometry characterization of the splenic immune populations from naïve and 
autoimmune mice. Flow cytometry analysis showing the different lymphoid and myeloid populations in 
the spleen of B/c, OPN-/-, Faslpr/lpr and OPN-/-Faslpr/lpr mice at time of sacrifice (5-6 months of age). 
Relative number of CD19+ cells was reduced in OPN-deficient autoimmune mice compared with OPN-
sufficient counterparts (***, P<0.001; Student t test), but their proliferation rate (CD19+Ki67+) was 
much higher in the same comparison (*, P<0.05; Stuent t test). CD3+B220+ autoimmune T cells 
diminished in the same group (**, P<0.01; Student t test). CD11b+ myeloid cells were enriched in OPN-
/-Faslpr/lpr compared with Faslpr/lpr mice (*, P<0.05; Student t test), due to an increase of Gr1hi cells (*, 
P<0.05, Student t test) and Ly6chi cells (**,  P<0.01, Student t test). Autoimmunity-associated pDCs were 
enriched in Faslpr/lpr compared to OPN-/-Faslpr/lpr spleens (**, P<0.01; Student t test. The graphs show a 
pool of two independent experiments.  
To confirm the flow cytometry analysis and to assess whether the absence of OPN also 
affected the spatial localization of the different immune cell subsets in the spleen in 
relation to the neoplastic clones, we performed IHC on spleen sections from both 
Faslpr/lpr and OPN-/-Faslpr/lpr mice for MPO (granulocytes), F4/80 (macrophages), CD4+ 
and CD8+ T cells (Fig. 43A). Despite MPO+ and F480+ myeloid cells are moderately 
present in the splenic parenchyma of both autoimmune mice without any relevant 
changes in tumorigenic spleens, their localization is at the edge of the lymphomatous 
zones (c-MYC+). T lymphocytes, both CD4+ and CD8+, are in close contact to the 




and OPN-/-Faslpr/lpr mice. In presence of lymphomas, while in Faslpr/lpr mice, CD4+ T 
cells are reduced, in OPN-/-Faslpr/lpr lymphomas at early stages they are still abundant 
and in contact with c-MYC+ tumor cells, whereas in late stages OPN-deficient 
lymphomas they are almost completely lost. The most significant finding is related to 
CD8+ cells, which are discretely present in the splenic autoimmune parenchyma of both 
strains and strongly increased in presence of lymphomas in Faslpr/lpr mice, and even 
more, in OPN-/-Faslpr/lpr  lymphomatous spleens. Another interesting feature of CD8+ T 
cells is that, only in the case of early OPN-deficient tumours, they showed the typical 
morphology of activated stellate T cells and heavily infiltrate the lymphomatous zones. 
These observations indicate that OPN-deficient tumours induce the recruitment of 
adaptive T cells that, however, seem to have a dysfunctional phenotype, as suggested by 
the expression of TIM3 and PD1, detected by flow cytometry analysis,  on CD8+ T 





                       
Figure 43. Evaluation of splenic immune population in situ. A) Double IHC on FFPE spleens for c-
MYC/MPO (tumour cells/granulocytes), c-myc/F480 (tumour cells/macrophages), c-MYC/CD4 and c-
MYC/CD8. Figures show that F480+ and MPO+ cells are present nearby the early stage lymphomas but 
are excluded from the representative lymphomatous zone of the late-stages tumours. CD4+ and CD8+, 
with an activated morphology in case of OPN-deficient mice, infiltrate lymphomatous areas. 
Magnification 20x. X. B) Flow cytometry graph showing that the percentage of CD8+TIM3+, likely 
exhausted cells, are significantly enriched (*, P<0.05, Student t test), while CD8+PD1+ showed a trend of 
increase, in OPN-/-Faslpr/lpr mice.  
 
Altogether, these data describe how lymphoid cells, more than the myeloid 
counterparts, abundantly infiltrate autoimmune and lymphomatous parenchyma, and 
that CD8+ infiltrating OPN-/- tumours are recruited but likely disfunctional. On the 
other hand, myeloid cells (granulocytes and macrophages,) are localised is at the edge 
of the lymphomatous areas.  
 
4.13 Stromal dynamics within the splenic microenvironment of OPN-/-
Faslpr/lpr mice cooperate in the process of B cell transformation 
 
Aiming at investigating whether also stromal dynamics regulated by OPN, other than B 
cell-intrinsic processes, contribute to the earlier and more aggressive lymphomagenesis 
of OPN-/-Faslpr/lpr mice, we wondered whether immune populations of the OPN-
deficient splenic microenvironment may better sustain B cell proliferation through the 
expression of factors that are important for their survival and/or activation. For this 
purpose, we evaluated the expression of Tnfsf13B, encoding for B cell activating factor 
(BAFF), in the different cell populations sorted from the spleen of BALB/c, OPN -/-, 




cells, CD4+, CD8+ T cells and, in the case of autoimmune mice, also autoreactive 
CD3+B220+ cells. Among the myeloid populations, gated on CD11b, we sorted 
granulocytic Gr-1hi cells, classical (CD11c+B220-) and plasmacytoid (CD11c+B220+) 
dendritic cells, and marginal macrophages (F480+CD169+). BAFF, member of TNF-
family, is crucial for B cell survival-related functions (such as protein synthesis and 
metabolism necessary to extend the half-life of immature, transitional, and mature B 
cells. [145]. Interestingly, we observed that the main producers of BAFF in the spleen 
of both naïve and autoimmune mice were Gr-1hi cells, showing expression levels 
significantly higher than all other immune cell populations (Fig. 44, upper panel). In 
general, its expression is higher in cells from autoimmune mice, which is consistent 
with a more inflamed and activated microenvironment than in naive mice. If we 
compare the expression of BAFF in Gr-1hi from the four different strains, granulocytic 
cells from OPN-/- mice showed a significant increase in the transcript level of Tnfsf13B 
in comparison to Gr1hi cells from BALB/c mice, and a similar trend, although not 
statistically significant, is maintained also in autoimmune mice (Fig. 44). Considering 
that Gr1hi cells are significantly enriched in the spleen of OPN-/-Faslpr/lpr mice compared 
with Faslpr/lpr mice, as shown in figure 42 and that this cell subset is the main producers 
of BAFF, the net result is an higher production of this factor in the spleen of OPN-/-
Faslpr/lpr mice.  
Notably, also F480+CD169+ marginal macrophages showed differences in the mRNA 
level of BAFF that was higher in OPN-/- macrophages, either from naïve or 
autoimmune mice (Fig. 44), despite the expression in this population was much lower 
than in granulocytic cells. 
As concerns CD4+ and CD8+ T cells, cDCs and pDCs, no significant differences in 





Figure 44. mRNA level of Tnfsf13b (BAFF) evaluated through RT-PCR on sorted splenic immune 
populations from B/c, OPN-/-, Faslpr/lpr and OPN-/-Faslpr/lpr mice. Gr1hi cells expressed the highest 
level of Tnfsf13b (upper panel). Gr1hi cells from OPN-/- spleens showed a significantly higher level of 
BAFF in comparison to B/c mice (*, P<0.05, Ordinary one way ANOVA), but only a trend was observed 
when comparing autoimmune animals. OPN-/- marginal zone macrophages (F480+CD169+) expressed a 
higher level of BAFF both in naïve (**, P<0.01,Ordinary one way ANOVA) and in autoimmune context 
(***, P<0.001; Ordinary one way ANOVA). Values are referred as 2^-DCT. A pool of 3 mice per group 
was used  
(Statistical significance is shown only in the graphs specific for each cell type for a matter of space). 
 
Additionally, since IL-6 is another molecule critical for B cell survival and it is a target 
gene of MYD88 signaling cascade, we evaluated its mRNA level in the same cell 
subsets from the four strains. Overall, almost all immune cells from OPN-deficient 
autoimmune mice, namely CD8+ T cells, Gr1hi, and cDCs showed a significant higher 
expression of Il6 in comparison with those from OPN-competent animals (Fig. 45). 
Among the different cell subsets, classical dendritic cells were the main producers of Il6 
(Fig. 45, upper panel). We observed a trend of increase in Il6 expression by CD4+ and 






Figure 45. mRNA level of Il6 evaluated through RT-PCR on sorted splenic immune populations 
from B/c, OPN-/-, Faslpr/lpr and OPN-/-Faslpr/lpr mice. Autoimmune classical DCs were the main 
producers of Il6 in comparison to the other cell subsets (graph above). OPN-/-Faslpr/lpr CD8+ cells (****, 
P<0.0001; Student t test), Gr1hi cells (*, P<0.05; Student t test) and cDCs (*, P<0.05; Student t test) 
expressed a significantly higher level of Il6 in comparison to Faslpr/lpr counterparts. CD4+ T cells and 
pDCs showed a similar trend. Values are referred as 2^-DCT. A pool of 3 mice per group was used. (data 
from Gr1hi cells from B/c and OPN-/- are not showed because RNA from the latter was not enough to 
perform RT-PCR (ND: Not done).  
(Statistical significance is shown only in the graphs specific for each cell type for a matter of space). 
 
 
Together, these results suggest that the also the stromal microenvironment may play a 
role in sustaining the lymphomatous phenotype observed in OPN-/-Faslpr/lpr mice, and 
that OPN may restrain the production of B cell-sustaining factors in specific immune 




4.14 OPN is down-regulated in human ABC-DLBCL in comparison 
with GC-DLBCL patient samples 
 
To assess the translation relevance of our findings and the potential role of OPN in 
human DLBCLs, we firstly analyzed its expression by IHC on biopsies derived from 
patients affected by different haematological diseases (5 per group), specifically 
follicular hyperplasia, GC- and ABC-DLBCL, follicular and mantle cell lymphomas 
(Fig. 46). Despite this was only a qualitative evaluation, we could appreciate how the 
highest expression of OPN was detected in biopsies of follicular- and germinal center-
related diseases, whereas it was poorly expressed in ABC-DLBCL compared to GC-
DLBCL samples, in line with our spontaneous mouse model, that develops ABC-like 
DLBCLs if genetically deficient for OPN. However, this staining does not clearly 
distinguish the cellular localization of the protein, nor it is definitely established the 
presence of a specific intracellular form of OPN in the human setting. 
 
Figure 46. IHC for OPN performed on human lymphoma biopsies. OPN is more expressed in 
follicular lymphoma and GC-DLBCL than mantle cell lymphoma and ABC-DLBCL. Magnification 20x 
(left) and 40x (right).  
 
Additionally, we performed some in silico analysis on a publicly available dataset, 
GSE4475, which compares gene expression profile from 221 DLBCL patients (58 




Volcano plot of figure 47A, comparing ABC- versus GC-DLBCL, 1411 genes were 
down-regulated and 1718 were up-regulated in the ABC-DLBCL group. Notably, SPP1 
was among the genes that were down-regulated in ABC-DLBCL (fold change: 1,75) 
(Fig. 47B), confirming the IHC data.  
Remarkably, PRDM1 (fold change: 1,12) and STAT3 (fold change: 2,53) expression 
were significantly higher in patients affected by ABC- than GC-DLBCL disease (Fig. 
47 B), in line with the data from our mouse models.  
 
Figure 47. Analysis of human dataset GSE4475. A. Volcano plot of differentially expressed genes 
calculated using limma linear models comparing ABC samples Vs GCB samples. P-value was corrected 
with the Benjamini and Hockberg method. Green dots represent down-regulated genes with FDR < 0.05 
and a negative log2 fold change, while red dots are up-regulated genes with a positive log2 fold change. 
B) Boxplots showing that SPP1 is downregulated, while PRDM1 and STAT3 up-regulated, in ABC VS 
GCB DLBCL samples. Dots in boxplot represent the expression of the selected genes in each sample.  
 
These results indicate that OPN-/-Faslpr/lpr lymphomas recapitulate the scenario of 
human ABC-DLBCL patients, with similar phenotype and gene expression of specific 
markers, and suggest that, also in human setting, OPN may exert a protective role, as 
patients affected by GC-DLBCL, which expresses higher levels of the protein, have 








This study demonstrates that osteopontin (OPN) protects autoimmunity-prone mice 
(Faslpr/lpr) from the development of B lymphomas. Indeed, Faslpr/lpr mice on OPN-
deficient background (OPN-/-Faslpr/lpr) showed a 2-fold increase in developing splenic 
diffuse large B cell lymphoma (DLBCL), of prevalent high-grade ABC-DLBCL 
subtype, than OPN-sufficient counterpart developing the less aggressive GC subtype. 
ABC-DLBCL was characterized based on the expression of BCL2 and IRF4 along with 
the absence of BCL6. Additionally, these cells express high level of the oncogene c-
MYC, thus suggesting that OPN-deficient tumors may belong to the very aggressive 
“double expressor” lymphoma subset, characterized by the concomitant expression of 
both c-MYC and BCL2 [73]. These features were conserved in the two lymphoma cell 
lines we have established from OPN-/-Faslpr/lpr mice, the “early stage” OPL239, and the 
“late stage” OPL241, both of the ABC-DLBCL subtype.  On the other hand, the few 
lymphomas developed in Faslpr/lpr animals showed a strong positivity for BCL6, a 
classical marker of human GC-DLBCLs, and negligible expression of the ABC-related 
proteins. Notably, a striking difference between lymphomas occurring in OPN-
competent and -deficient mice was the higher activation of STAT3 pathway in absence 
of OPN, suggesting that OPN-/-Faslpr/lpr tumours may rely on this signaling pathway for 
their proliferation/survival. 
OPN-deficient autoimmune mice showed a significant increase in a splenic CD93- 
mature population, a CD23-CD21/35- fraction that comprises neither follicular 
(CD23+) nor marginal zone (CD21/35+) B cells. This result suggests that OPN may act 
as a brake in the expansion of these “atypical” cells and that the accumulating CD23-
CD21/35- fraction in OPN-/-Faslpr/lpr mice may represent the B cells undergoing 
malignant transformation toward ABC-DLBCs. In agreement with this hypothesis, also 
OPL239 and OPL241 cell lines are negative for these markers. 
The hypothesized underline mechanism is that B cell-intrinsic OPN is able to prevent 
the exacerbation of autoimmunity-driven B cell transformation, through the impairment 
of MYD88 signaling pathway. In absence of OPN, a striking up-regulation of Toll-like 
receptor 9 (TLR9) occurring on splenic CD19+ B cells, could likely increase the 




Indeed, an increase in MYD88-protein machinery (i.e. IRAK1, IRAK4 and MYD88) 
was observed both in steady state conditions and after stimulation with CpG 1826, a 
TLR9 agonist. Accordingly, OPN-deficient autoimmune B cells are more activated, 
(higher CD86 expression) than OPN-sufficient counterparts. These findings seem to 
contradict the well-established role of OPN in promoting processes leading to 
inflammation and cancer [110,120]. Such discrepancy may be explained by the fact that 
OPN isoform generally associated with the hallmarks of cancer is the secreted (sOPN) 
[97,131, 132] rather than the intracellular one (iOPN). Indeed, the more recently 
identified iOPN exerts some anti-inflammatory activities [101,119,146], that fit well 
with our findings. The co-localization and interaction between iOPN and the scaffold 
protein MYD88 has been documented in a few reports [101,108], although with 
different outcomes. One report shows that iOPN promotes MYD88-mediated IFNα 
production in plasmacytoid dendritic cells [108], while the other one demonstrates that 
the lack of OPN in macrophages results in a more activated NFkB pathway and that 
replacing iOPN in these cells antagonize this cascade. [101] Despite not investigate for 
iOPN-MYD88 co-localization, another paper shows that iOPN negatively controls 
TLR4-mediated inflammation by regulating GSK3β and 4EBP1 phosphorilation [146]. 
The results I have presented are in agreement with the two latter works in supporting an 
anti-inflammatory role of iOPN.  Indeed, the presence of iOPN in B lymphocytes in the 
spleen of autoimmune mice was documented by IHC showing an intracellular staining 
of the protein, characterized by evident dots surrounding the peri-nuclear region.  
Furthermore, the lymphomatous areas arising in Faslpr/lpr mice showed a further increase 
in the OPN expression, that preserved an intracellular localization. Immunofluorescence 
on cytospin preparations also showed that OPN and the endosomal marker CD63 
display the same pattern of expression in B cells from Faslpr/lpr mice, demonstrating that 
iOPN exerts is role in the endosomal compartment, where TLR9 resides. These results 
are the first showing the presence and the anti-inflammatory role of iOPN in 
autoimmune B lymphocytes. 
In a translational perspective, the findings of more active TLR9-MYD88 signaling in 
OPN-/-Faslpr/lpr mice are in line with the well-established hyper-activation of MYD88 
pathways detected in human DLBCLs, which, however, is mainly due to activating 
mutations in MYD88 gene [84].  




overexpressing either the secreted or the intracellular isoform of OPN into OPL239 and 
OPL241 DLBCL cell lines and comparing the activation of key pathways such as 
STAT3 and NF-kB. Results showed that the forced expression of iOPN inhibited their 
activation, either at steady state or upon CpG 1826 stimulation. Accordingly, when 
intravenously injected in sub-lethally irradiated BALB/c mice, OPL239 cells over-
expressing the iOPN form showed a significantly slower growing tumor in the spleen 
than Spp1-overexpressing and control transduced (IRES Green) cells.  
Together, these evidences strongly suggest that B-cell intrinsic iOPN constrasts 
lymphomagenesis in Faslpr/lpr mice, exerting a negative feed-back loop on STAT3 and 
NFkB signaling cascades, a process otherwise promoted in its absence (OPN-/- mice). 
Neverthless, 33% of Faslpr/lpr mice still develop B cell lymphomas, in an OPN-
competent setting, suggesting that, in mice characterized by the highest inflammation 
associated with autoimmune conditions, the endogenous iOPN is not sufficient to 
restrain B cell transformation. The increased expression of iOPN detected in B cells 
from lymphomatous areas of Faslpr/lpr mice, in comparison to naïve mice, may represent 
an unsuccessful attempt to restrain STAT3 and NFkB signaling activation.   
During B cell differentiation in secondary lymphoid organs, a distinct pattern of genes 
is transcribed or repressed in a controlled manner. BLIMP1 is a master regulator of 
plasma cell differentiation, and it is repressed during the initial germinal center reaction, 
while upregulated in the post-activated state of B cell maturation [88]. In line with these 
notions and with the phenotype of DLBCL developed in OPN-/-Faslpr/lpr mice, GEP of 
splenic B cells from autoimmune mice showed a 7,3-fold increase of Prdm1, encoding 
for BLIMP1, in B cells derived from OPN-/-Faslpr/lpr mice, compared with those from 
Faslpr/lpr mice at 5 months of age, a time point in which most OPN-/-Faslpr/lpr mice show 
already signs of lymphomas, whereas OPN-competent Faslpr/lpr mice do not. However, 
as far as hematological malignancies are concerned, BLIMP1 is usually genetically 
inactivated or transcriptionally repressed in DLBCL [92], being activated as a tumor 
suppressor. However, my data are not in disagreement with the reported literature, as 
both PRDM1α and PRDM1β transcriptional variants are generally expressed only in 
non-GCB subtype of DLBCL and, additionally, PRDM1β correlated with short survival 
in non-GCB patients treated with CHOP [95]. Interestingly, BLIMP1 belongs to the 
MYDD88-NFkB axis, as LPS-stimulated B cells from MYD88-/- mice show decreased 




of Prdm1 expression in OPN-deficient lymphomas, detected in the GEP and confirmed 
in situ by RNA Scope technique, is in line with the aggressive ABC phenotype 
characterizing lymphomas developing in OPN-/-Faslpr/lpr mice.  
Other than B cell-intrinsic, the dynamics promoting the aggressive lymphomagenesis 
described in OPN-deficient autoimmune mice likely involve the stromal compartment. 
Indeed, OPN is expressed also by other immune cells of the splenic microenvironment 
of Faslpr/lpr mice, as shown at transcript and protein levels in both lymphoid (mainly 
CD4+ T cells and autoimmune CD3+B220+ cells) and myeloid cells (mainly 
granulocytes).  Generally speaking, lymphoid cells are known to produce the secreted 
protein that acts as a pro-inflammatory cytokine by binding surface receptors and 
promoting inflammatory signaling cascades, whereas the intracellular form has been 
shown to be produced by cells of the myeloid lineage [103,119,132]. My data are in line 
with the reported literature, as autoimmune CD3+B220+ are “pro-inflammation” by 
definition, and are present in the Faslpr/lpr spleen and also in the peripheral blood, where 
they likely release a consistent amount of OPN. In agreement, increasing levels of OPN 
have been detected by ELISA in the serum of Faslpr/lpr mice along autoimmune disease 
progression. Also, IHC on Faslpr/lpr spleen sections showed OPN expression in 
granulocytes and other myeloid cells in granulomas and the perivascular zone of the red 
pulp. As for B cell-expressed OPN, also in this case the staining is suggestive of an 
intracellular localization. 
Remarkably, the immune cell subsets, of either lymphoid or myeloid lineage, 
populating the spleen of OPN-Faslpr/lpr mice, express factors important for B cell 
survival and proliferation at higher level than OPN-competent counterparts. Specifically, 
CD169+F480+ marginal macrophages from OPN-deficient animals, regardless the 
naïve or autoimmune conditions, expressed significantly more Tnfsf13b (BAFF) than 
OPN-competent counterpart, and Gr1hi granulocytic cells showed a similar trend. 
Additionally, CD8+ T cells, Gr1hi granulocytes and classical dendritic cells from OPN-
/-Faslpr/lpr mice showed a higher expression of Il6 than Faslpr/lpr animals.  
These data suggest that the OPN-/-Faslpr/lpr splenic microenvironment, providing 
additional supporting factors for B cell proliferation/survival, may contribute to the 
exacerbated ABC-DLBCL development observed in these animals.  




phenotype, changes occurred in the splenic immune cell subsets between Faslpr/lpr and 
OPN-/-Faslpr/lpr mice. CD3+B220+ autoimmune cells and plasmacytoid dendritic cells, 
the latter known to have important roles in autoimmune disorders, were up-regulated in 
OPN-competent autoimmune mice, characterized for a more severe autoimmunity. On 
the other hand, myeloid cells (CD11b+), and more specifically the Gr-1hi granulocytic 
and the Ly6Chi monocytic subsets, were expanded in the spleen of OPN-/-Faslpr/lpr mice. 
These observations are in agreement with an article showing how myeloid–specific 
OPN is able to negatively regulate cell cycle and survival of cells of the myeloid lineage 
during emergency myelopoiesis [119]. Interestingly, the observed expansion of Gr-1hi 
cells is in line with previous data from our laboratory, showing that tumor-induced 
myelopoiesis was increased in OPN-deficient versus OPN-competent mice bearing 
solid tumours [132].  
Beside their relative number, the topographic distribution of the different immune 
populations in a tissue may be even more relevant for their interaction and cross-talk. 
Indeed, although no significant differences in terms of percentage of T cells were noted 
by flow cytometry, IHC analysis provided evidences of CD4+ and CD8+ T cells 
intermingled with the lymphomatous B cells in early and, even more, in late-stage 
lymphomas. While CD4+ T cells, particularly Follicular Helper T cells, are known to 
exert a pivotal role in autoimmune disorders [37,38], the presence of CD8+ T cells 
within the lymphomatous zones was unexpected whereas suggestive of a possible 
immunogenicity of transformed cells, perhaps capable to induce some kind of immune 
response, although abortive. On this line, CD8+ T cells in lymphomas from OPN-
deficient mice are bigger than in OPN-competent mice and showed a star-shaped 
morphology, suggestive of an activated state. Flow cytometry analysis however 
indicated that CD8+ T lymphocytes from OPN-/-Faslpr/lpr spleen express higher level of 
the exhaustion marker TIM3 than those from OPN-competent animals. These data 
suggest that, in the context of the aggressive OPN-/- lymphomas, CD8+ cells are 
recruited locally and activated, but incapable of an efficient anti-tumour response 
because the local microenvironment render them exhausted.  
The association between low/absent OPN and DLBCL of the ABC type in a translation 
setting was confirmed by IHC on ABC- versus GC-DLBCL biopsies. Also, in silico 
analysis on publicly available dataset showed a down-regulation of the OPN gene, 




Interestingly, in the same comparison, PRDM1 and STAT3 were significant up-
regulated in ABC-DLBCL biopsies, in line with our findings in the mouse model 
showing higher expression of these proteins in OPN-deficient lymphomas, supporting 
our hypothesis of an opposite regulation of OPN versus STAT3 and BLIMP1.   
In conclusion, our study indicates that B cell-intrinsic iOPN has a protective role from 
autoimmunity-driven lymphomagenesis contrasting TLR9-MYD88-related programs of 
proliferation and inflammation. Beside B cell-intrinsic effects, also microenvironment-
related OPN, likely the intracellular isoform of the protein expressed by cells of the 
myeloid lineage, contributes in protecting B cells from transformation, limiting the 
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